For non-commercial use only
  
PROTOCOL
Brigatinib in Patients With Anaplastic Lymphoma Kinase- Positive (ALK +), Advanced 
Non–Small -Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Sponsor: ARIAD Pharmaceut icals, Inc
a who lly owned subsidiary of Takeda
Pharmaceut ical Co mpany Limited
40 Landsdowne Street
Cambridge, MA 02139 USA
Telephone: +1 (617) 679 -7000
Study Number: 2002
IND Number: IND 110,935 EudraCT Number: 2018-000635-27
Compound: Brigatinib (AP26113)
Date: 12February 2021 Amendment 5
Version Number: 1.0
Amendment History
Date Amendment Number Type Region
12 February 2021 5 Substantial Global 
24 September 2020 4 Substantial Global 
27 September 2019 3 Substantial Global
10 April 2019 2 Substantial Global
11 December 2018 1 DE v1 Nonsubstantial Germany
12 October 2018 1 SE v1 Nonsubstantial Sweden
03 May  2018 1 Nonsubstantial Global
22 February 2018 Initial Protocol Not applicable Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement 
by the recipient that no information contained herein will be published or disclosed without written authorization 
from Takeda except to the exte nt necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her 
staff, and applicable institutional review committee and regu latory  agencies to enable conduct of the study. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 2of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL1.0 ADMINISTRATIVE 
1.1 Contacts 
A separate contact informat ion list will be provided to each site.
Serious adverse event and pregnancy reporting information are presented in Sect ion10.0, as i s 
inform ation on reporting product complaints. 
Invest igators will be provided wit h emergency  medical contact informat ion cards to be carried 
by each subject.
General a dvice on protocol  procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in study  manual  to the si te.
The names and contact informat ion for the m edical m onitor and responsible medical officer are 
in the study  manual .
For non-commercial use only
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 4of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL1.3 Protocol Amendment 5 Summary and Rationale
This sect ion describes the changes in the protocol incorporating Amendment 5. The primary 
reasons for this amendment are to:
Modify definit ion of end of study .
Provi de posttri al access to bri gatinib.
Add language around photosensit ivity.
Modify the storage condit ions for the study  drug.
Clarify  that no pharmacokinet icsamples shoul d be collected going forward.
Supply  information on wi thdrawal of pat ients from the study.
Make I ndependent Review Committee assessment of images opti onal after the primary  
analysis.
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are not included. 
Protocol Amendment 5
Summary of Changes Since the Last Version of the Approved Protocol
No. Section(s) Affected by Change Description of Each Change and Rationale
Location(s) Description Rationale
1 Cover page, Amendment History 
tableDate of Amendment 4 corrected 
from 18 to 24 September 2020Correct typo graphical error in 
date
2 1.2, Approval Changed statistical approver Assignment change
3 Section 6.3.2 , End of 
Study/Study Completion 
Definitio n and Planned 
ReportingModified definition of end of 
study to include termination of 
study by sponsor. Correct prior omission
4 Section 6.3.5 , Posttrial Access Section added to provide posttrial 
access to brigatinibCorrect prior omission
5 Section 8.4.2 , Pulmonary 
Adverse Reaction s, 
Photosensitivity, and Other 
Adverse EventsAdd language around 
photosensitivity to sunlightNew information available
6 Section 8.12, Storage, Handling, 
and AccountabilityModify storage conditions New storage condition s
7 Section 9.4.19 , Pharmacokinetic 
Measurements
Appendix A, Schedules of 
Events , PK Sampling ScheduleAs of Amendment 5, no additional 
pharmacokinetic (PK) samples 
should be collectedBecause the primary analysis has 
been conducted, this will help to 
close the study out from a 
bioanaly tical perspective
8 Section 9.8, Withdrawal of
Patients From StudySection added Correct prior omission
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 5of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALProtocol Amendment 5
Summary of Changes Since the Last Version of the Approved Protocol
No. Section(s) Affected by Change Description of Each Change and Rationale
Location(s) Description Rationale
9 Section 11.2, Independent 
Review CommitteeIndependent Review Committee
assessment of images may be 
discontinued following the 
primary  analy sisOptional at sponsor discretion
10 Appen dix G, Protocol Histor y Add summary of Amendment 4 Takeda template
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 6of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALINVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the investigator’s brochure, and any 
other product informa tion provi ded by the sponsor. I agree to conduct this study  in accordance 
with the requi rements of this protocol and also to protect the rights, safet y, privacy, and well -
being of study  subjects in accordance wit h the fo llowing:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulato ry requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the clinical study  site agreement.
Responsibilit ies o f the invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this proto col.
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 7of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE ....................................................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 5 Summary  and Rat ionale........................................................ 4
2.0 STUDY SUMMARY .................................................................................................... 12
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 16
3.1 Study -Related Responsibilit ies................................................................................. 16
3.2 Principal Invest igator ............................................................................................... 16
3.3 List of Abbreviat ions............................................................................................... 17
3.4 Corporate Identificat ion........................................................................................... 18
4.0 INTRODUCTION ......................................................................................................... 19
4.1 Background ............................................................................................................. 19
4.1.1 Epidemi ologyand Pathol ogy........................................................................... 19
4.1.2 ALK+ NSCLC .................................................................................................19
4.1.3 Current Treatment for ALK+ NSCLC .............................................................. 20
4.1.4 Unmet Medical Need ....................................................................................... 21
4.2 Brigatinib................................................................................................................. 21
4.3 Rationale for the Proposed Study ............................................................................. 22
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 23
5.1 Object ives................................................................................................................ 23
5.1.1 Primary Object ive............................................................................................ 23
5.1.2 Seco ndary  Object ives...................................................................................... 23
5.1.3 ................................................................... 24
5.2 Endpoints ................................................................................................................. 24
5.2.1 Primary Endpo int............................................................................................. 24
5.2.2 Secondary  Endpo ints....................................................................................... 24
5.2.3 .................................................................... 25
6.0 STUDY DESIGN .......................................................................................................... 25
6.1 Overview of Study  Design ....................................................................................... 25
6.2 Number of Patients .................................................................................................. 27
6.3 Durati on of  Study .................................................................................................... 27
6.3.1 Durati on of  an Individual Pat ient’s Study  Parti cipati on.................................... 27
6.3.2 End of Study /Study  Com pletion Definit ion and Pl anned Reporting .................. 27
6.3.3 Timeframes for Primary and Secondary  Endpo ints to Support Disclosures ......27
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 8of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL6.3.4 Total  Study  Durati on....................................................................................... 28
6.3.5 Posttrial Access ............................................................................................... 28
7.0 STUDY POPULATION ................................................................................................ 29
7.1 Inclusio n Cri teria................................
..................................................................... 29
7.2 Exclusio n Cri teria.................................................................................................... 30
8.0 STUDY DRUG ............................................................................................................. 32
8.1 Study  Drug Adm inistrati on...................................................................................... 32
8.2 Reference/Control Therapy ...................................................................................... 33
8.3 Treatment Bey ond Radi ological Disease Progression ............................................... 33
8.4 Dose Modificat ion Guidelines .................................................................................. 33
8.4.1 Dose Modificat ion for Brigatinib -Related Adverse Events ............................... 34
8.4.2 Pulmo nary Adverse React ions, Photosensit ivity, and Other Adverse Events ....38
8.5 Prior and Concomi tant Therapies ............................................................................. 39
8.6 Excluded Conco mitant Medi cations and Procedures ................................................ 40
8.7 Permi tted Concomitant Medications and Procedures ................................................ 41
8.8 Precauti ons and Restri ctions.................................................................................... 41
8.8.1 Pregnancy, Breastfeeding, and Contraception .................................................. 41
8.9 Blinding and Unblinding .......................................................................................... 42
8.10 Descript ion of Invest igational Agents ...................................................................... 42
8.11 Packaging and Labeling ........................................................................................... 42
8.12 Storage, Handling, and Accountabilit y..................................................................... 43
8.13 Other Protocol -Specified Materials .......................................................................... 43
9.0 STUDY CONDUCT ...................................................................................................... 43
9.1 Study  Person nel and Organizations .......................................................................... 43
9.2 Arrangements for Recruit ment of Patients ................................................................ 44
9.3 Treatment Group Assignments ................................................................................. 44
9.4 Study  Procedures ..................................................................................................... 44
9.4.1 Inform ed Consent ............................................................................................ 44
9.4.2 Patient Dem ographi cs...................................................................................... 44
9.4.3 Screening ......................................................................................................... 45
9.4.4 Enrollment ....................................................................................................... 45
9.4.5 Medical Hi story............................................................................................... 45
9.4.6 Physical Examinat ion...................................................................................... 46
9.4.7 Patient Hei ght and Weight ............................................................................... 46
9.4.8 Vital Signs....................................................................................................... 47
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 9of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL9.4.9 Concomitant Medications and Procedures ........................................................ 47
9.4.10 AEs ................................................................................................................. 47
9.4.11 ECG ................................................................................................................ 47
9.4.12 Clinical Laboratory  Evaluat ions....................................................................... 47
9.4.13 Pregnancy Test ................................................................................................ 48
9.4.14 Disease Assessment ......................................................................................... 48
9.4.15 End-of-Treatm ent Visi t.................................................................................... 50
9.4.16 Thirty-Days -After -Last-Dose Visit .................................................................. 50
9.4.17 Follow-up Peri od............................................................................................. 50
9.4.18 Biomarker, Pharmacodynamic, and PK Samples .............................................. 51
9.4.19 Pharmacokinet ic Measurements ....................................................................... 52
9.4.20 QOL Assessment: EORTC QLQ- C30 and QLQ- LC13 .................................... 53
9.4.21 .......................................................................... 53
9.4.22 Heal th Utilizat ion Data Collect ion................................................................... 54
9.5 Com pletion of Study  Treatm ent (f or Individual Patients) ......................................... 54
9.6 Com pletion of Study  (for Individual Pat ients).......................................................... 54
9.7 Discontinuati on of  Treatment Wi th Study  Drug ....................................................... 54
9.8 Withdrawal o f Patients From  Study ......................................................................... 55
9.9 Study  Com pliance .................................................................................................... 55
9.10 Overall Survival ....................................................................................................... 56
10.0 ADVERSE EVENTS .................................................................................................... 56
10.1 Definit ions............................................................................................................... 56
10.1.1 PTE Definit ion................................................................................................ 56
10.1.2 AE Definit ion.................................................................................................. 56
10.1.3 AE Se verity..................................................................................................... 57
10.1.4 SAE Definit ion................................................................................................ 57
10.2 Procedures for Recording and Reporting AEs and SAEs .......................................... 58
10.3 Moni toring of AEs and Period of Observat ion......................................................... 59
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 59
10.5 Procedures for Reporting Product Complaints or Medicat ion Errors (Including 
Overdose) ................................................................................................................ 59
10.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties........... 60
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 60
11.1 Steering Committee .................................................................................................60
11.2 Indep endent Review Co mmittee .............................................................................. 60
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 61
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 10of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL12.1 eCRFs ...................................................................................................................... 61
12.2 Record Retention ..................................................................................................... 61
13.0 STATISTICAL METHODS .......................................................................................... 62
13.1 Statistical and Analyt ical Plans ................................................................................ 62
13.1.1 Analysis Sets ................................................................................................... 62
13.1.2 Analysis of Demographics and Other Baseline Characterist ics......................... 63
13.1.3 Efficacy Analysis ............................................................................................. 63
13.1.4 Pharmacokinet ic Analysis ................................................................................ 65
13.1.5 Subgroup Analysis in Pat ients Progressed on Alectinib .................................... 65
13.1.6 Analysis of Patient -Reported Outcomes and Healt h Resource Utilizat ion 
Data ................................................................................................................. 65
13.1.7 Safety Analysis ................................................................................................ 65
13.2 Sample Si ze Just ification ......................................................................................... 66
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 66
14.1 Study -Site Moni toring Visit s................................................................................... 66
14.2 Protocol  Deviat ions.................................................................................................. 67
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 67
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 67
15.1 Benefit -Risk o f the Study ......................................................................................... 68
15.2 IRB and/or IEC Approval ........................................................................................ 68
15.3 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 69
15.4 Subject Confidentialit y................................ ............................................................ 70
15.5 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................71
15.5.1 Publicat ion....................................................................................................... 71
15.5.2 Clinica l Trial Registrati on................................
................................................ 71
15.5.3 Clinical Trial Result s Disclosure ...................................................................... 71
15.6 Insurance and Co mpensation for Injury .................................................................... 72
16.0 REFERENCES .............................................................................................................. 72
LIST OF IN -TEXT TABLES
Table 6.a Secondary  Endpo ints for Di sclosure................................................................... 28
Table 8.a Reco mmended Brigat inib Dose Reduction Levels .............................................. 34
Table 8.b Brigatinib Dose Modification Reco mmendat ions for Treatment -Related 
Adverse Events .................................................................................................. 35
Table 9.a Clinical Chemistry  and Hematol ogy Tests .......................................................... 48
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 11of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTable 9.b Primary Specimen Collection ............................................................................. 51
LIST OF IN -TEXT FIGURES
Figure 6.a Study  Design ...................................................................................................... 26
LIST OF APPENDICES
Appendix A Schedules of Events ........................................................................................... 76
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 83
Appendix C Invest igator Consent to Use of Personal Informat ion.......................................... 85
Appendix D Eastern Cooperative Oncology  Group Scal e for Perf ormance Status .................. 86
Appendix E Response Eval uation Cri teria In Solid Tum ors (RECIST Version 1.1) ............... 87
Appendix F Modificat ion of Diet in Renal Disease Equation for Estimated Glomerul ar 
Filtration Rate .................................................................................................... 90
Appendix G Protocol  History.................................................................................................91
For non-commercial use only
For non-commercial use only
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 14of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALMain Criteria for Inclusion:
1.Have histologica lly or cytologically confirmed stage IIIB (locally advanced or recurrent and not a candidate for 
curative therapy) or stage IV NSCLC.
2.Must meet both of the following 2 criteria:
a)Have documentation of ALK rearrangement by a positive result from any laboratory  test approved by the 
Food and Drug Administration (FDA) (eg, the Vysis ALK Break Apart FISH [fluorescence in situ 
hybridization] Probe Kit or the Ventana ALK [D5F3] CDx [companion diagnostic] Assay or Foundation 
Medicine’s FoundationOne CDx)
or
Have documented ALK rearrangement by a different test (non –FDA -approved local lab tests) and have 
provided tumor sample to the central laboratory (Note: Central laboratory ALK rearrangement testing 
results are not required to be obtained before randomizati on.)
b)The patient had been treated with any 1 of the ALK tyrosine kinase inhibitors (TKIs) (alectinib, ceritinib, 
crizotinib) for at least 12 weeks before progression. 
3.Had progressive disease while on alectinib or ceritinib (defined as no more than 1 month from last dose of 
alectinib or ceritinib to disease progression, as assessed by the investigator or treating physician). (Number of 
patients not previously treated with alectinib will be capped at 10 for every 30 patients enrolled.)
4.Had alectinib or cerit inib as the most recent ALK inhibitor therapy. Chemotherapy before or after progression 
on alectinib or ceritinib is allowed. 
5.Have at least 1 measurable lesion per RECIST version 1.1 as assessed by the investigator. 
6.Recovered from toxicities related to p rior anticancer therapy to National Cancer Institute Common Terminology 
Criteria for Adverse Events version 4.03 Grade ≤1. (Note: Treatment -related alopecia or peripheral neuropathy 
that are Grade >1 are allowed if deemed irreversible.)
7.Have Eastern Cooper ative Oncology Group performance status ≤1.
8.Have adequate organ and hematologic function.
Main Criteria for Exclusion:
1.Received any prior ALK -targeted TKI other than crizotinib, alectinib, or ceritinib.
2.Received both alectinib and ceritinib.
3.Received criz otinib, alectinib, or ceritinib within 7 days of the first dose of brigatinib. 
4.Previously received more than 3 regimens of systemic anticancer therapy for locally advanced or metastatic 
disease.
Note: A systemic anticancer therapy regimen will be counted if it is administered for at least 1 complete cycle. A 
new anticancer agent used as maintenance therapy will be counted as a new regimen. Neo -adjuvant or adjuvant 
systemic anticancer therapy will be counted as a prior regimen if disease progression/recurre nce occurred within 
12months upon completion of this (neo -)adjuvant therapy.
1.Have symptomatic brain metastasis (parenchymal or leptomeningeal). Patients with asymptomatic brain 
metastasis or who have stable symptoms that did not require an increased dose of corticosteroids to control 
symptoms in the past 7 days before the first dose of brigatinib may be enrolled.
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is confirmed ORR, as assessed by the independent review committee , per 
RECIST version 1.1 in full analysis set.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 15of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALStatistical Considerations:
The purpose of this phase 2 study is to determine the confirmed ORR of orally administered brigatinib at current 
clinical doses ( ≤180 mg QD) in patients with ALK+ NSCLC whose disea se progressed after therapy on alectinib or 
ceritinib. The sample size was determined so that it would allow for stating that the true ORR (expected response 
rate) is greater than the threshold response rate of 20% for patients previously treated by alecti nib or ceritinib. A 
sample size of 103 patients will be enrolled. This sample size was calculated to provide at least 90% power to rule 
out an uninteresting ORR of 20%, assuming the true ORR is 35%. The calculation is based on an exact binomial test 
with a one-sided alpha level of 0.025 at primary endpoint analysis, allowing for dropout.
The final analysis of the primary endpoint will be conducted approximately 6 months after the last patient is 
enrolled. ORR will be tested at a one -sided alpha of 0.025. If the primary endpoint is achieved in patients previously 
treated with alectinib or ceritinib, then a subgroup analysis of confirmed ORR in patients previously treated with 
alectinib will be performed and tested at a one -sided alpha of 0.025.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 16of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL3.0 STUDY REFERENCE INFORMATIO N
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
study  manual . The i dentified vendors in the study manual for specific study -related activit ies will 
perform  these act ivities in full or in partnership wit h the sponsor.
3.2 Principal Investigator
Takeda will select a Signatory  Coordinat ing Investigator from the invest igators who participate 
in the study . Selection cri teria for this invest igator will include si gnificant knowledge of the 
study  protocol , the study  medicat ion, thei r expert ise in the therapeutic area and the conduct of 
clinical research as well as study  parti cipat ion. The Si gnatory  Coordinat ing Invest igator will be 
requi red to revi ew and sign the cl inical study  report and by doing so agrees that it accurately 
describes the results of the study .
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 17of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL3.3 List of Abbreviations
AE adverse event
ALK anaplastic lymphoma kinase
ALK+ anaplastic lymphoma kinase -positive
ALT alanine aminotransferase
AST aspartate aminotransferase
BCRP breast cancer resistance protein
CNS central nervous system
COVID -19 coronavirus disease 2019
CPK creatine phosphokinase
CR complete response
CRO contract research organization
CT computed tomography
ctDNA circulating tumor DNA
CYP cytochrome P -450
DCR disease control rate
DLT dose-limiting toxicity
DOR duration of response
DTP direct -to-patient
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form 
EDC electronic data capture
EOPE early  onset pulmo nary event
EORTC European Organization for Research and Treatment of Cancer
EQ VAS European Quality of Life Scale Visual Analogue Scale
EU European Union
FDA Food and Drug Administration
FFPE formalin -fixed paraffin -embedded
FISH fluorescence in situ hybridization
GCP Good Clinical Practice
GI gastrointestinal
HRQOL health -related quality of life
HU health resource utilization
IB investigator’s brochure
IEC independent ethics committee
ICF informed consent form
ICH International Conference on Harmonisation
ILD interstitial lung disease
iORR intracranial objective response rate
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 18of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALiPFS intracranial progression -free survival
IRB institutional review board
IRC independent review committee
KD kinase domain
LD longest diameter(s)
MATE multidrug and toxin extrusion protein
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NSCLC non–small -cell lung cancer
OCT1 organic cation transporter 1
ORR objective response rate
OS overall survival
PD progressive disease
PFS progression -free survival
Pgp P-glycoprotein
PK pharmacokinetic(s)
PR partial response
PRO patient -reported outcomes
PTE pretreatment event
QD once daily
QOL quality  of life
RECIST Response Evaluation Criteria in Solid Tumors
SAE serious adverse event
SAP statistical analysis plan
SD stable disease
SLD sum of the longest diameters
SOE Schedule of Events
SRS stereotactic radiosurgery
SUSAR suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
TKI tyrosine kinase inhibitor
TRAE treatment -related adverse event
ULN upper limit of normal
US United States
3.4 Corporate Identification 
ARIAD ARIAD PHARMACEUTICALS INC, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 19of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
4.1.1 Epidemiology and Pathology
Lung cancer is one of the most commo n cancers in the world (1.8 millio n new cases in 2012), 
which was 12.9% of all new cancers worldwide [1]. Globally , lung cancer accounte d for 
1.6millio n cases and 1.4 millio n deaths in 2008 [
2].It is the l eading cause of cancer death in the 
United States (US) and in the European Unio n (EU). In the US, an estimated 234,030 new cases 
of lung cancer will be diagnosed by  end of 2018, and 154,050 deaths due to the disease are 
estimated to occur [
3]. In the EU, lung cancer is ranked as the fourth most frequent cancer; 
approximately  313,000 new cases were diagnosed in 2012 and 268,000 deaths in that y ear [1]. 
Five
-year survival rates remain low: 17.7% and 13% in the US and Europe, respectively [4,5]. In 
Japan, l ung cancer i s ranked as the third most frequent cancer; approximately 113,000 new cases 
were di agnosed in 2012 and approximately 71,500 deaths in that y ear (Center for Cancer Control 
and Information Services, National Cancer Ce nter, 2017). Most lung cancer cases are diagnosed 
at advanced stages and about 78% of newly diagnosed patients have regio nal/distant disease [
1]
[
5].
Historically, l ung cancers have been stratified on the basis o f histol ogic criteria and are generally 
divided into 2 categories: small -cell lung cancer and non –small -cell lung cancer (NSCLC). 
NSCLC is the most prevalent histologic class, accounting for nearly 85% of all lung cancers 
[
6,7], and includes a numbe r of subt ypes such as adenocarcino ma, squamous -cell carcino ma, 
large -cell carcinom a, and bronchio loalveo lar carcino ma [
8]. In recent y ears, attenti on has turned 
to stratifying lung cancer pat ients on the basis o f molecular alterations since it has beco me clear 
that histol ogically  identical tumors are driven by different oncogenes and are ther efore likely to 
respond different ly to therapeutic intervent ion, such as therapies directed at epithelial growth 
factor receptor (EGFR) -mutant, anaplast ic lymphoma kinase -rearranged (ALK+), c -ros oncogene 
1 (ROS1) rearranged, or BRAF V600E mutant NSCLC. Th e focus herein is on NSCLC that 
contains oncogenic rearrangements in the ALK gene, and the role of brigatinib, a novel 
small -molecule inhibitor, in the treatment of ALK+ NSCLC. 
4.1.2 ALK+ NSCLC
ALK is a ty rosine kinase encoded on chromosome 2 and is primarily i nvolved in developmental 
processes and expressed at low levels in adults [
9]. The first genet ic rearrangement of ALK seen 
in NSCLC invo lved a fusio n between the EML4 gene and the ALK tyrosine kinase do main (KD). 
EML4 -ALK has the capa city to transform  fibroblasts grown in culture and as subcutaneous 
xenografts to induce tumor format ion [
10]. Since then, a number of addit ional ALK fusio n 
partners have been described in NSCLC that are believed to re sult in aberrant signaling and 
oncogenic transformat ion [11,12]. 
Estimates of the frequency o f ALK rearrangement in the overall populat ion of NSCLC patients 
range fro m 2% to 7% [
13,14] , whi ch represent, on the basis o f proporti onali ty of total  
popul ations in the US and EU, approximately 7000 to 25,000 ALK+ NSCLC pat ients in the US 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 20of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALand 5800 to 20,000 pati ents in the EU in 2016. ALK rearrangements are more commo n among 
patients wi th adenocarcinom a histol ogy, pati ents who have never smoked, and patients who have 
wild-type EGFR and Kirsten rat sarcoma virus oncogene [9]. 
4.1.3 Current Treatment for ALK+ NSCLC
While the standard treatment algorithm for unselected NSCLC patients has historically invo lved 
front line treatment with chemotherapy, recent clinical trials have demonstrated that patients with 
ALK+ locally advanced or met astati c NSCLC respond well to treatment with the ALK inhibitors 
(crizotinib, alectinib, and cerit inib).
Crizotinib received accelerated approval fro m the US Food and Drug Administration (FDA) in 
2011 on the basis o f resul ts from 2single -arm studies [
15]. 
The efficacy of crizotinib has been confirmed in a ran domized study  of crizotinib versus 
chemotherapy [
15,16] .
ALK -dependent mechanisms o f resistance, observed in approximately 30% of pat ients [
17], 
include the acquisit ion of secondary mutations in ALK that interfere wit h crizotinib binding, 
and/or amplificat ion of the ALK fusio n gene. More than 10 secondary  mutations in ALK have 
been associated with crizotinib resistance in pat ients, with the most commo n being L1196M and 
G1269A [
18,19] . The central nervous system (CNS) i s the first si te of progressi on in 
approximately  50% of  patients treated with crizotinib [20,21] , suggesting inadequate penetration 
of crizotinib into the brain (ie, pharmaco logic failure) as the pri mary  cause of  resistance in these 
patients. Therefore, an ALK inhibitor that can overcome secondary  resistance m utations in ALK, 
has adequate penetration into the CNS, and is less suscept ible to pharmaco logic failure, m ay be 
requi red to overcome resistance .
Recent ly, 2 other ALK inhibitors, cerit inib [22]and al ectinib [23], have beco me available for 
NSCLC pat ients with ALK rearrangements. Both drugs are effect ive in pat ients previously 
treated with crizotinib. Cerit inib demo nstrated significant ly improved progression -free survival 
(PFS) vers us chemotherapy  (hazard rati o 0.55) [24] whereas alect inib demo nstrated significant ly 
improved PFS versus crizotinib (hazard ratio 0.34 -0.47) [25,26] in treatment -naïve ALK+ 
advanced NSCLC. 
ALK secondary  mutationsassoci ated wi th clinical  resistance to ceri tinib and alect inib have also 
been ident ified, including L1152R and F1174C/V for ceritinib, I1171N/T/S for alect inib, and 
G1202R for both agents [
18,27-30] .
More recent ly, the invest igational agent lorlatinib has been evaluated in a phase 1/2 trial showing 
responses after ≥1 prior ALK tyrosine kinase inhibitor (TKI) (25% [11 of 44] object ive response 
rate (ORR) in patients with 2 prior ALK TKIs and 31% [4 of 13] ORR in patients with 3 prior 
ALK TKIs). The most commo n treatment -related adverse events (TRAEs) were 
hypercho lesterol emia (90%) and hypertriglyceridem ia (72%) [
31]. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 21of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL4.1.4 Unmet Medical Need
Significant progress has been made with incorporation of ALK TKIs for treatment of ALK+ 
NSCLC, but eventually  almost all patients progress on these TKIs. The alternative treatments for 
these patients include chemotherapy and checkpo int inhibit ors (PD -1 or PD -L1 antibody). The 
efficacy  of platinum doublet chemotherapy  seems not to be impacted by  prior TKI treatm ent, but 
the efficacy  was limi ted wi th a response rate of about 30% and median PFS of about 
4months[32]. Checkpo int inhibito rs have been introduced into the market recent ly as treatment 
for NSCLC. These agents are particularly  effect ive in pat ients whose tumors over -express PD -L1 
and have less benefit in pat ients with EGFR m utation or ALK rearrangements [
33], possibly 
related to l ow m utation burden in this populat ion characteri zed by  nonsm oking status [
34]. 
There i s still high unmet medical need for these ALK+ NSCLC pat ients progressed on alect inib 
or ceri tinib to have access to an efficacious targeted therapy (evidenced by higher ORR and 
durable responses) and adequate CNS penetration with robust intracrania l responses. Such a new 
therapeuti c opti on coul d prol ong disease control and translate into improved lo ng-term outcom es 
including longer PFS. These efficacy attributes of a new therapy , along wi th a favorable safet y 
profile, are needed for this patient pop ulation.
4.2 Brigatinib
Brigatinib (AP26113) is a novel, orally administered (PO) TKI discovered and developed by 
ARIAD Pharmaceut icals, Inc (ARIAD; Cambridge, Massachusetts), a wholly owned subsidiary 
of Takeda Pharmaceut ical Company Limit ed. Primary  targets are activated mutant forms o f ALK 
and ROS1, which play  important rol es in NSCLC and other cancers. 
A series o f in vitro and in vivo studies demonstrated that brigatinib potently inhibited ALK 
activit y and proliferat ion in ALK+ cell lines and exhibited a g reater than 100
-fold select ivity 
over ALK- negat ive lines. 
In clinical study , brigat inib has an acceptable safety  profile at the recommended dose of 90 mg 
once daily  (QD) f or 7 day s, then 180 m g QD, continuously (hereinafter presented as 90 mg 
QD→180 m g QD ). Bri gatinib at this dose level exhibited substant ial efficacy  in patients wi th 
ALK+ NSCLC who had progressed on crizotinib. In 110 patients, the confirmed response rate 
was 56.4% (62 of 110, 97.5% CI: 45.2, 67.0) by  independent revi ew committee (IRC) 
assessment. The IRC -assessed median duration o f response (DOR) was 15.7 months (95% CI: 
12.8, 21.8 event rate: 54.8%) and median PFS was 16.7 months (95% CI: 11.6, 21.4, event rate: 
49.1%). Hi gh IRC -assessed intracranial object ive response rate (iORR) (66.7%, 12 of 18, 95% 
CI: 41.0, 86.7) with a median 16.6 months (95% CI: 3.7, Not Reached) duration of intracranial 
response was also observed in pat ients with measurable baseline brain metastases by IRC 
(ALTA study , data cut- off: 29 September 2017, data on file) . On 28 April 2017, the FDA granted 
accelerated approval to brigat inib (ALUNBRIG) for the treatment of patients with metastatic 
ALK+ NSCLC who have progressed on or are intolerant of crizotinib. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 22of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL4.3 Rationale for the Proposed Study
Second- generat ion ALK TKIs, including alect inib and cerit inib, have shown efficacy, including 
durable response to intracranial lesio ns, and have an acceptable safet y profile in both ALK TKI 
treatm ent-naïve and pretreated patients. Both alect inib and ceri tinib were approved as first -line 
treatm ent for ALK+ advanced NSCLC in US and European countries. However, resistance to 
alectinib and cerit inib develops eventually, wit h emergence of secondary resistant mutations 
detected in approximately 50% of patients [33].
Brigatinib (AP26113) is a novel, synt hetic, orally active ALK TKI. A pre -clinical study [35]
revealed that assessed at concentrations relative to the level o f exposure achieved in pat ients at 
the approved or recommended phase 2 doses, brigatinib was the m ost potent inhibitor compared 
with crizotinib, cerit inib, and alectinib. Brigat inib inhibits 17 clinically and preclinically 
observed crizotinib -, ceri tinib-and/or al ectinib -resistant ALK m utations. Com pared wi th these 3 
ALK TKIs, brigatinib also exhibite d superi or preclinical act ivity when in vitro potencies were 
related to steady -state pl asma level  of each drug achieved in pat ients at the approved dose. 
Amo ng the 4 ALK TKIs tested, brigat inib was the only TKI to maintain substant ia
l activi ty 
against the most recal citrant G1202R m utant in vivo. Brigat inib also has act ivity in a mice 
orthotopic brain model metastasis. 
In the ALTA study , the 90 m g QD →180 m g QD treatm ent regimen was associated with a higher 
confirmed ORR and lo nger PFS, as well as improved i ntracranial efficacy, as co mpared with the 
90 m g QD regimen. Therefore, there appears to be a relationship between dose/exposure and 
efficacy , which suggests that hi gher brigat inib doses may result in better efficacy. However, 
higher brigat inib doses/expos ures were associated with so me treatment -related Grade 3 or higher 
adverse events (AEs) (eg, increased creatine phosphokinase [CPK], skin and subcutaneous tissue 
disorders and rash) 
(https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000TO C.cfm). A 
240mg QD dose of brigatinib was determined to be the highest acceptably tolerated dose in 
Study  AP26113 -11-101. As a result, in the present study , pati ents who progress on brigat inib 
180mg QD will have the option to receive brigat inib at an inc reased dose of 240 mg QD in an 
effort to provide better mutational coverage. Patients will be allowed to receive only the 240 mg 
QD bri gatinib dose postprogression if they have not experienced toxicit ies greater than Grade 2 
after the 180 m g brigat inib dos e.
The rati onale for escalat ion to 240 m g QD at disease progression is to provide an opportunit y at 
progression for treatment at higher exposures of brigat inib that may consequent ly provide 
clinical benefit through a greater degree of ant itumor activit y compared to 180 mg and/ or to 
attem pt to overcom e potenti al pharmacol ogic resistance at 180 mg QD brigat inib (ie, to increase 
brigatinib exposure in order to have better activit y against a given ALK KD resistance mutation 
or for increased exposure in the CNS ).
In study  AP26113 -
11-101, 10 pati ents were enrolled to receive brigatinib 240 mg QD, of which 
1 pati ent experi enced a dose -limit ing toxicit y (DLT) of Grade 3 alanine aminotransferase (ALT) 
elevation. Treatm ent-
emergent adverse events (TEAEs) leading to d ose interrupti on, reduction, 
or discontinuati on occurred at similar rates for patients dosed at 90 mg QD →180 m g QD (56.3% 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 23of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL[18 of 32], 18.8% [6 of 32], and 12.5% [4 of 32], respect ively) and 240 mg QD brigat inib (50.0% 
[5 of 10], 20.0% [2 of 10], and 10.0% [1 of 10], respect ively). Co mmo n TEAEs were similar for 
patients dosed at 90 mg QD →180 m g QD and 240 mg QD brigat inib and included 
gastrointestinal [GI], constitutional, and pulmo nary events. Data from studies AP26113 -11-101 
and AP26113 -13-201 indicate the incidence of early onset pulmo nary events (EOPEs) is related 
to the init ial dose of brigat inib, but EOPEs have not been observed upon dose escalat ion 
(ie,90mg QD →180 m g QD regimen). Therefore, it is expected that patients who tolerate 
brigatinib at 180 mg QD and then escalate to 240 mg QD will not have an increased risk of 
EOPEs after escalat ion.
In separate but similar studies, ALK+ patients taking brigat inib after progressing on crizotinib, 
had a l onger median PFS as assessed by IRC (15.6 months, 95% C I: 11.1, 21.0, ALTA study, 
data cut: 29 September 2017) than those taking alectinib (8.9 months, [36]and 7.1 months, [37], 
both by  IRC assessment) or cerit inib (5.7 months, by invest igator assessment, [38]). 
On the basis of nonclinical and clinical data, brigatinib may be efficacious in pat ients who 
developed resistant mutations to alectinib or cerit inib or those who do not respond to alectinib or 
ceritinib because of pharmacol ogic resistance. This phase 2 study  is designed to assess the 
clinical efficacy  and safet y of brigatinib in ALK+ advanced NSCLC pat ients who have 
progressed on alect inib or cerit inib.
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Obje ctive
The primary  object ive of the study  is to determine the efficacy  of brigat inib, as evidenced by 
confirmed ORR, in patients with ALK+ locally advanced or metastatic NSCLC whose disease 
has progressed on therapy  with alect inib or cerit inib. 
5.1.2 Secondary O bjectives
The secondary objectives are:
To characterize the durabilit y of efficacy wit h brigatinib. 1.
To assess intracranial efficacy o f brigatinib. 2.
To assess the overall survival (OS) with brigat inib. 3.
To assess the safet y and tol erabilit y of brigatinib. 4.
To collect pl asma concentrati on-time data for brigatinib to contribute to populat ion 5.
pharmacokinet ic (PK) analyses.
To assess pat ient-reported symptoms and health- related quali ty of life (HRQOL) assessed by 6.
European Organizat ion for Research and Treatment of Cancer (EORTC) QLQ -C30 and 
QLQ -LC13.
For non-commercial use only
For non-commercial use only
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 26of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALFigure 6.a Study Design
Abbreviations: ALK+, anaplastic lymphoma kinase positive; NSCLC, non –small - cell lung cancer; FDA, Food and 
Drug Administration; TKI, tyrosine kinase inhibitor, PD, progressive disease.
ALK+ by central laboratory is not required before enrollment.
Strongly encourage (but not mandate) re -biopsy at screening and at progression. Plasma sample to be collected at 
screening, Cycle 3 Day 1 and Cy cle 5 Day  1 and at progression.
Patients will  cont inue to be treated with br igatinib unt il they experience object ive disease 
progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicit y. 
Upon radio logical progressi on, at the discretion of the invest igator, patients who are receiving 
brigatinib 180 m g QD and have experienced toxicities no greater than Grade 2 during treatment 
may elect to increase the brigat inib dose to 240 mg QD, or continue study treatment at their 
current dose if they are st ill benefit ing from treatment at this dose (eg, absence of clinical 
symptoms or signs indicating clinically significant disease progression requiring alternat ive 
systemic anti -cancer therapy; no decline in performance status; absence of rapid disease 
progression or threat to vital organs or critical anatomical si tes [eg, respi ratory  failure due to 
tumor com pressi on, spinal cord compression] requiring urgent use of alternat ive ant icancer -
therapy; and no significant, unacceptable or irreversible toxicit ies related to study  treatm ent). In 
both scenarios (increase dos e or continue at same dose), the medical monitor shall review and 
approve the case.
AEs will be assessed fro m the time informed consent is signed till 30 days after last dose. 
Patients’ signs and symptoms, laboratory  values, vi tal signs, el ectrocardi ogram s(ECGs), and any 
other rel evant special exams as clinically indicated will be obtained to evaluate the safety  and 
tolerabilit y of brigatinib.
Sparse PK samples will be co llected during the study  to m easure pl asma concentrations of 
brigatinib, as outlined i n Appendix A, PK Sam pling Schedule.
Toxicit y will be evaluated according to National Cancer Inst itute Commo n Termino logy Criteria 
for Adverse Events ( NCI CTCAE), version 4.03, effective 14 June 2010 [39]. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 27of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL6.2 Number of Patients
The total number of patients is approximately  103. 
6.3 Duration of Study
6.3.1 Duration of an Individual Patient’s Study Participation
Patients will  cont inue to be treated with brigat inibuntil they experience object ive disease 
progression per RECIST version 1.1, as assessed by the investigator, or intolerable toxicit y. Wit h 
medical mo nitor approval, treatment may  be cont inued at 180 mg QD or may be escalated to 
240mg QD after init ial pro gression if there is st ill potenti al for clinical benefi t.
The fo llow-up peri od for survival begins after the patient has permanent ly discontinued study 
drug and continues unt il pat ient dies, i s lost to f ollow-up, withdraws consent or the study ends, 
which ever com es first. Patients who discont inue the study  drug for reasons other than 
radiological  disease progressi on shall st ill be followed for tumor assessment according to the 
protocol  until radio logical disease progression is observed. For patients who qu alify and elect to 
receive brigatinib 240 mg QD, the survival fo llow-up begins after they  have di scontinued study  
drug.
6.3.2 End of Study/Study Completion Definition and Planned Reporting
The study  will end when all pat ients die or 3 years have passed since the last patient started study  
treatm ent or the study  is terminated by  the sponsor, whi chever com es first. 
6.3.3 Timeframes for Primary and Secondary Endpoints to Support Disclosures
The stud y will start enrollment in 2018 and the overall t imeframe will be pending on final 
sample size. 
Please refer to Table 6.afor disclosures information for all primary  and secondary  endpoints.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 28of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTable 6.a Secondary Endpoints for Disclosure
Endpoint
Primary : Confirmed ORR, as assessed by the IRC.
Secondary: 
1.Confirmed ORR, as assessed by the investigator (per RECIST version 1.1).
2.DOR, as assessed by the investigator and IRC.
3.PFS as assessed by the investigator and IRC.
4.DCR as assessed by the investigator and IRC.
5.Time to response as assessed by the investigator and IRC.
6.Confirmed intracranial ORR in patients with brain metastases at baseline, as assessed by the IRC.
7.Intracranial DOR in patients with brain metastases at baseline, as assessed by the IRC.
8.Intracranial PFS in patients with brain metastases at baseline, as assessed by the IRC.
9.Overall surv ival.
10.Safety/tolerability (per CTCAE version 4.03).
11.HRQOL assessed with the global health status/quality of life and other function and symptom (per EORTC 
QLQ -C30 version 3.0, and EORTC QLQ -LC13).
Abbreviations: CNS: central nervous system; CTCAE, Common Terminology Criteria for Adverse Events; DCR, 
disease control rate; DOR, duration of response; EORTC, European Organization for Research and Treatment of 
Cancer; HRQOL, health -related quality of life; IRC, independent review committee; ORR, objective respo nse rate; 
PFS, progression -free survival; RECIST, Response Evaluation Criteria in Solid Tumors .
6.3.4 Total Study Duration
The study  will end around 5 y ears after enrollment starts, taking into considerat ion enrollment 
and fo llow-up. 
6.3.5 Posttrial Access
Posttrial access to bri gatinib may be provided by the sponsor. Con tinued access to brigat inib for 
participants will be terminated for those individuals who no longer benefit fro m brigatinib 
(eg,they have com pleted the recommended course of therapy  or thei r disease has resolved), the 
benefit -risk no l onger favors the individual, if brigatinib beco mes available eit her commercially 
or via another access mechanism, or when an alternat ive appropriate therapy  becomes available. 
Posttrial access m ay be terminated in a country  or geographical region where marketing 
authori zation has been rejected, the development of brigatinib has been suspended or stopped by  
the sponsor, or the brigatinib can no l onger be supplied.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 29of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL7.0 STUDY POPULATION
7.1 Inclusion Criteria
Each patient must meet all of the fo llowing inclusion cri teria to be enrolled in the study :
Have histologically or cy tologically  confirmed stage IIIB (locally advanced or recurrent and 1.
not a candidate for curative therapy ) or stage IV NSCLC.
Must meet both of the fo llowing 2 cri teria: 2.
a)Have documentation of ALK rearrangement by  a posi tive result fro m any laboratory  test 
approved by  the FDA (eg, the Vy sis®ALK Break -Apart fluorescence in situ 
hybridizat ion [FISH] Probe Kit or the Ventana ALK [D5F3] CDx Assay or Foundation
Medicine’s Foundat ionOne CDx).
or
Have documented ALK rearrangement by  a different test (non –FDA -approved l ocal lab 
tests) and have provided tumor sample to the central laboratory . (Note: Central laboratory  
ALK rearrangement testing results are not requir ed to be ob tained before rando mizat ion.)
b)The pati ent had been on any  one of  the ALK TKIs (al ectinib, cerit inib, crizotinib) for at 
least 12 weeks before progression. 
Had progressive disease (PD) while on alect inib or cerit inib(defined as no more than 3.
1month from last dose of alect inib or cerit inib to disease progression, as assessed by the 
investigator or treating physician). (Number of patients not previously treated with alect inib 
will be capped at 10 for every  30 pati ents enrolled.)
Had al ectinib or cerit inib as the most recent ALK inhibitor therapy . Chemotherapy before or 4.
after progressi on on alect inib or cerit inib is allowed. 
Have at least 1 measurable lesio n per RECIST version 1.1 as assessed by the invest igator. 5.
Recov ered from toxi cities related to prior anticancer therapy  to NCI CTCAE, versi on 4.03, 6.
Grade ≤1. (Note: Treatment -related alopecia or peripheral neuropathy that are Grade >1 are 
allowed if deemed irreversible.)
Male or female, 18 y ears or ol der or of l ocal legal adul t age . 7.
Have a life expectancy  of ≥3 m onths. 8.
Have adequate organ and hematologic function as determined by:9.
a)ALT/aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN); ≤5 × ULN is 
acceptable if liver metastases are present. 
b)Total  serum bilirubin ≤1.5 × ULN (<3.0 × ULN for patients with Gilbert syndro me).
c)Estimated glo merular filtration rate (eGFR) ≥30mL/min/1.73 m2, using the modification 
of diet in renal disease (MDRD) equation ( Appendix F). 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 30of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALd)Serum  lipase ≤1.5 × ULN.
e)Absol ute neutrophil  count ≥1.5 × 109/L. 
f)Platelet coun t ≥75 × 109/L.
g)Hem oglobin ≥9g/dL.
h)Have Eastern Cooperative Onco logy Group (ECOG) performance status <1.
For fe male patients of childbearing potential, have a negat ive pregnancy test documented 10.
≤7days before start of study  medicat ion.
Female pat ients of childbearing potential and male patients with partners of childbearing 11.
potenti al must agree to use a hi ghly effe ctive nonhorm onal form of contracepti on wi th their 
sexual partners during the dosing period and for a period of at least 4 months after the end of 
treatm ent (Secti on 8.8.1).
Have the willingness and abilit y to comply with scheduled visit and study  procedures and 12.
provi de a si gned and dated informed consent indicating that the patient has been informed of 
all pertinent aspects of the study , including the p otent ial risks, and is willingly participat ing.
7.2 Exclusion Criteria
Patients m eeting any o f the following exclusio n criteri a are not to be enrolled in the study :
Received any  prior ALK -targeted TKI other than crizotinib, alect inib, or ceritinib. 1.
Received bo th alectinib and ceri tinib. 2.
Received crizotinib, alectinib, or cerit inib wit hin 7 days of the first dose of brigat inib. 3.
Previously  received m ore than 3 regimens of systemic anticancer therapy  for locally  4.
advanced or metastatic disease.
Note: A sy stemic anticancer therapy regimen will be counted if it is administered for at least 
1 com plete cycle. A new ant icancer agent used as maintenance therapy will be counted as a 
new regimen. Neo -adjuvant or adjuvant systemic ant icancer therapy  will be counted as a 
prior regimen if disease progression/recurrence occurred within 12 mo nths upon complet ion 
of this (neo -)adjuvant therapy .
Received chemotherapy  or radi ation within 14 days of first dose of brigat inib, except for 5.
stereotacti c radiosurgery  (SRS) or stereotact ic body radiat ion therapy . 
Received anticancer monoclonal ant ibodies wit hin 30 day s of the first dose of brigat inib. 6.
Had m ajor surgery  within 30 days of the first dose of brigat inib. Minor surgical procedures 7.
such as catheter placement or minimally invasi ve biopsies are allowed. 
Have been diagnosed with another primary malignancy other than NSCLC, except for 8.
adequately  treated n onmelano ma skin cancer or cervical cancer in situ; definit ively treated 
nonmetastati c prostate cancer; or patients with another p rimary malignancy who are 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 31of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALdefinit ively relapse -free with at least 3 years elapsed since the diagnosis of the other primary 
malignancy.
Have symptomat ic brain metastasis (parenchymal or leptomeningeal). Patients with 9.
asymptomat ic brain metastasis or who hav e stable symptoms that di d not requi re an 
increased dose of corticosteroids to control symptoms in the past 7 days before the first dose 
of brigat inib may be enro lled. 
Have current spinal cord compressio n (symptomat ic or asymptomat ic and detected by 10.
radiographic imaging). Patients with leptomeningeal disease and without cord compression 
are allowed.
Have significant, uncontrolled, or active cardio vascular disease, specifically including, but 11.
not restricted to: 
a)Myocardial  infarct ion within 6 months before the first dose of brigat inib.
b)Unstable angina wit hin 6 mo nths before first dose of brigat inib.
c)Congest ive heart failure wit hin 6 months before first dose of brigat inib.
d)History  of clinically  significant atri al arrhy thmia (including clinically significant 
bradyarrhyt hmia), as determined by the treating physician.
e)Any history  of clinically significant ventricular arrhy thmia.
Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose 12.
of brigat inib.
Have uncontrolled hyperten sion. Pati ents wi th hypertensi on shoul d be under treatment on 13.
study  entry  to control  blood pressure.
Have a history  or the presence at baseline o f pulmonary  interstitial disease, drug -related 14.
pneumo nitis, or radiat ion pneumo nitis. 
Have an ongo ing or activ e infect ion, including, but not limit ed to, the requirement for 15.
intravenous ant ibiotics.
Have a known history  of HIV infect ion. Testing is not required in the absence of history. 16.
Have malabsorption syndrome or other GI illness that could affect oral absorp tion of  17.
brigatinib.
Have a known or suspected hy persensi tivity to brigatinib or i ts exci pients. 18.
Are pregnant, planning a pregnancy, or breastfeeding. 19.
Have any condit ion or illness that, in the opinion of the invest igator, would compro mise 20.
patient safet y or interfere wi th the evaluat ion of brigatinib.
Received systemic treatment with strong cy tochrome P -450 (CYP)3A inhibitors, moderate 21.
CYP3A inhibitors, strong CYP3A inducers, or moderate CYP3A inducers within 14 days 
before enro llment (refer to Section 8.6for a list of example medicat ions).
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 32of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL8.0 STUDY DRUG
8.1 Study Drug Administration
In extenuating circumstances, such as during the COVID -19 public healt h em ergency, addi tional 
drug supply may be provided to the subjects to cover periods between on -site visi ts. Addi tional 
study  drug m ay be dispensed during a scheduled study  visit, or study  drug m ay be shipped 
directly from invest igational sites to participants ’ residences by a contracted logist ics provi der or 
distributor (di rect-to-patient [DTP] shipment) in agreement with Takeda processes and local 
healt h authorit ies. 
Before init iation of the DTP process, patients will agree to participate in this process. Patients 
will sign a separate acknowledgment of receipt form permitt ing this process and agree to share 
limited personal informat ion with the delivery couri er. The invest igator and courier must ensure 
that no pri vate pati ent inform ation is shared with the sponsor or other CROs participating in the 
study . The l ocal institutional review board (IRB)/independent ethics committee (IEC) must be 
notified, as applicable per lo cal requi rements, that thi s process i s being init iated, and sites must 
clearly  document the chain of custody  of any study drug di spensed di rectly to patients. 
Brigatinib will be administered orally at a dose of 90 mg QD for the first 7 day s. Pati ents who 
have tol erated the 90 mg starting dose on Days 1 through 7 will be expected to increase their 
dose to 180 mg QD beginning on Day  8 and cont inuously every day, with a 28 -day study  
procedure execut ion cycle. The study  drug shall be taken approximately at the same time of the 
day each day . It m ay be taken wi th or wi thout f ood. Pati ents shall be instructed to swallow the 
tablets who
le and not crush or chew them. Patients will take the dose with water (recommended 
240mL). If a dose of brigat inib is missed or vo miting occurs after taking a dose, do not 
administer an addit ional dose and take the next dose of brigatinib at the scheduled time.
The patient's daily dose of brigatinib should not be increased to 180 mg if any of the fo llowing 
adverse reactions are exper ienced during treatment at 90 mg QD:
Intersti tial lung disease (ILD)/pneumo nitis (any grade).
Symptom atic bradycardia (Grade 2 or greater).
Grade 2 or higher visual disturbance.
Any other Grade 3 or higher adverse reaction.
A missed dose is defined as a do se not taken within 6 hours of the intended scheduled 
administration. Missed doses should be recorded in an appropriate source record (eg, clinic chart, 
patient diary  card) and study  drug administration electroni c case report form (eCRF) . If a dose of 
study drug i s missed or vomit ing occurs after taking a dose, do not administer an addit ional dose 
and take the next dose of study  drug at the scheduled time.
All protocol -specific criteria for administration of study  drug m ust be m et and docum ented 
before drug administration. Study  drug will be administered only to eligible pat ients under the 
supervisio n of the invest igator or ident ified subinvestigator(s).
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 33of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL8.2 Reference/Control Therapy
Not applicable.
8.3 Treatment Beyond Radiological Disease Progression
Until radio logical disease progression is ident ified, patients may cont inue to receive brigatinib at 
current dose, if they  are st ill benefit ing fro m it as determined by invest igator (eg, absence o f 
clinical symptoms or signs indicating clinically significant disease pr ogression requiring 
alternat ive systemic ant icancer therapy; no decline in performance status; absence o f rapid 
disease progressi on or threat to vital organs or critical anatomical sites [eg, respiratory  failure 
due to tum or com pressi on, spinal cord compre ssion] requi ring urgent use of alternat ive 
anticancer -therapy; and no significant, unacceptable or irreversible toxicit ies related to study  
treatm ent). Pati ents will  be requi red to provi de consent to receive treatment bey ond progression. 
Patients who have progressed on brigatinib 180 mg QD and have had no greater than Grade 2 
brigatinib -related toxi city will be given the opti on to increase the dose to 240 mg QD unt il 
radiological  disease progressi on per RECIST, using the tumor assessment before dose escala tion 
as the new baseline, is observed or intolerance. Patients will be required to provide consent to 
receive this increased dose of brigat inib.
In either scenario, m edical m onitor del egated by  the sponsor shall review and approve the case 
and an informed consent shall be obtained fro m the pati ent. The pati ent shall continue to receive 
the efficacy , safet y, patient report outcome and healt h resource utilizat ion assessments as in the 
main study  treatm ent phase. 
8.4 Dose Modification Guidelines
The fo llowing sect ions provide reco mmended dose -modificat ion gui delines for treatm ent-related 
AEs observed with brigatinib administration.
The allowable daily doses of brigat inib in this study  are 240 m g (applicable only for patients 
eligible to increase to 240 m g after disease progression), 180 mg, 120 mg, 90 mg, and 60 mg. 
When pat ients are intolerant of their current dose they will have the option to reduce their dose in 
accordance with the dose -reduction scheme shown in Table 8.a.
Dose interruptions or reductions should be implemented for patients who experience treatment -
related AEs, upon clinical judgment of the invest igator. Study  drug administrat ion may be 
delayed for up to 28 days to allow for improvement or resolution of the event. Patients may  have 
an interrupti on in therapy  for 14 days shoul d em ergency surgery  be clinically  indicated.
NOTE: If brigat inib treatment interruption lasts ≥14 day s, and prior dose was >90 mg QD, 
patients shoul d resume treatment at 90 mg QD for 7 day s, before escalat ing dose back to 120 mg 
QD or 180 mg QD. The dose should not be escalated higher than the prior dose level before 
treatm ent interruption.
If an AE does not resolve to Grade 1 or less after dose interruption for more than 28 days, the 
sponsor’s medical mo nitor must be contacted.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 34of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALRe-escalat ion after dose modificat ion for AEs i s discouraged. However, if, in the opinio n of the 
treating investigator, re -escalat ion is warranted, this must be undertaken after consultation wit h 
the sponsor. To be a candidate for re -escalat ion, the AE that led to dose modificat ion must not 
have recurred, and no other AEs of Grade 3 or 4 must have been observed during the preceding 
28 days.
Com prehensive assessments of any  study  drug -related AEs (ie, adverse drug reactions) 
experienced by the patient will be performed throughout the course of the study . The severi ty of 
the event, as well as clinical judgment, will be utilized to determi ne appropri ate m anagement of 
the pati ent for any  AE experienced while participating in this study .
Any medicat ion, including those administered for therapy of symptoms considered associated 
with study  drug administration, should be reported on the appropri ate concomitant medication 
page of the patient’s eCRF.
8.4.1 Dose Modification for Brigatinib -Related Adverse Events
The minimum dose for brigat inib is 60 mg QD. If a patient cannot tolerate study  drug at thi s dose 
level, the study  drug shall be permanent ly disc ontinued. The dose reduction levels o f brigatinib 
are listed in Table 8.a. 
Table 8.a Recommended Brigatinib Dose Reduction Levels
Dose Reduction Levels
Starting Dose First Second Third Fourth Fifth
90 mg QD 60 mg QD Permanently 
discontinueNot applicable Not applicable Not applicable
180 mg QD 120 mg QD 90 mg QD 60 mg QD Permanently 
discontinueNot applicable
240 mg QD a180 mg QD 120 mg QD 90 mg QD 60 mg QD Permanently 
discontinue
Abbreviation: QD, once daily.
aFor patients who tolerated 180 mg dose and had increased dose to 240 mg QD at disease progression.
8.4.1.1 General TRAEs
Guidelines for dose m odificati on of  brigat inib treatment -related AEs are outlined in Table 8.b
and are based on the Company Core Data Sheet (CCDS) for brigatinib. Unless otherwise noted, 
reduce dose as shown in
 Table 8.bif 1 or more dose reduction is necessary because of adverse 
reacti ons of  Grade 3 or 4 severit y, as defined by  NCI CTCAE versio n 4.03.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 35of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTable 8.b Brigatinib Dose Modification Recommendations for Treatment -Related 
Adverse Events
Adverse Reaction Severity* Dose Modification
ILD/pneumonitis Grade 1 If new pulmonary symptoms 
occur during the first 7 days of 
treatment, withhold brigatinib 
until recover y to baseline, then 
resume at same dose and do not 
escalate to 180 mg if 
ILD/pneumonitis is suspected.
If new pulmonary symptoms 
occur after the first 7 days of 
treatment, withhold brigatinib 
until recover y to baseline, then 
resume at same dose.
If ILD/pneumonitis recurs, 
permanently discontinue 
brigatinib.
Grade 2 If new pulmonary symptoms occur 
during t he first 7 day s of treatment, 
withhold b rigatinib until recovery to 
baseline. Resume at next -lower dose 
(Table 8.a) and do not dose -escalate 
if ILD/pn eumonitis is suspected.
If new pulmonary symptoms 
occur after the first 7 days of 
treatment, withhold brigatinib 
until recover y to baseline, then 
resume at same dose.
If new ILD/pneumonitis recurs, 
permanently discontinue 
brigatinib.
Grade 3 or 4 Permanently discontinue brigatinib 
for ILD/pneumonitis.
Hypertension Grade 3 hypertension (SBP greater than 
or equal to 160 mmHg or DBP greater 
than or equal to 100 mmHg, medical 
interventio n indicated, more than one 
antihy pertensive drug, or more intens ive 
therapy  than previously used indicated).Withhold brigatinib until 
hypertensio n has recovered to 
baseline or SBP less than 140 
mmHg and DBP less than 90 
mmHg, then resume brigatinib 
at same dose ( Table 8.a).
Recurrence: Withhold brigatinib 
until recover y to Grade 1 or less, 
and resume at next -lower dose 
(Table 8.a) orpermanently 
discontinue treatment.
Grade 4 hypertension (life -threatening 
consequences, urgent intervention 
indicated).Withhold brigatinib until 
recover y to Grade 1 (SBP less 
than 140 mmHg and DBP less 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 36of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTable 8.b Brigatinib Dose Modification Recommendations for Treatment -Related 
Adverse Events
Adverse Reaction Severity* Dose Modification
than 90 mmHG), and resume at
next-lower dose ( Table 8.a) or
permanently discontinue 
treatment.
Recurrence of Grade 4 
hypertensio n: Permanently 
discontinue brigatinib.
Bradycardia (HR less than 60 
bpm) Symptomatic b radycardia Withhold brigatinib until 
recover y to asymptomatic 
bradycardia or to a resting heart 
rate of 60 bpm or above.
If a concomitant medication 
known to cause bradycardia is 
identified and discontinued or 
dose-adjusted, resume b rigatinib 
at same dose upon recover y to 
asymptomatic bradycardia or to 
resting heart rate of 60 bpm or 
above.
If no concomitant medication 
known to cause bradycardia is 
identified, or if contributing 
concomitant medications are not 
discontinued or dose -adjusted, 
resume b rigatinib at next -lower 
dose ( Table 8.a) upon recovery 
to asymptomatic bradycardia or 
to resting heart rate of 60 bpm 
or above.
Bradycardia with life -threatening 
consequences, urgent intervention 
indicatedPermanently discontinue 
brigatinib if no contributing 
concomitant medication is 
identified.
If contributing concomitant 
medication is identified and 
discontinued or dose -adjusted, 
resume b rigatinib at next -lower 
dose ( Table 8.a) upon recovery 
to asymptomatic bradycardia or 
to a resting heart rate of 60 bpm 
or above, with frequent 
monitoring as clinically 
indicated. 
Recurrence: Permanently 
discontinue brigatinib.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 37of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTable 8.b Brigatinib Dose Modification Recommendations for Treatment -Related 
Adverse Events
Adverse Reaction Severity* Dose Modification
Visual disturbance Grade 2 or 3 visual disturbance Withhold brigatinib until recover y to 
Grade 1 or baseline, then resume at 
the next -lower dose ( Table 8.a).
Grade 4 visual disturbance Permanently discontinue brigatinib.
CPK elevation Grade 3 or 4 CPK elevation (greater than 
5.0 × ULN) with Grade ≥2 muscle pain or 
weaknessWithhold brigatinib until 
recover y to Grade 1 or less 
(≤2.5 × ULN) CPK elevation or 
to baseline , then resume 
brigatinib at same dose.
If a Grade 3 or 4 elevation of 
CPK recurs with Grade ≥2 
muscle pain or weakness, 
brigatinib should be withheld 
until recover y to Grade 1 or less 
(≤2.5 × ULN) or to baseline, 
then resume at the next lower 
dose level per Table 8.a.
Lipase/amy lase elevation Grade 3 (>2.0 × ULN) Withhold brigatinib until 
recover y to Grade 1 or less 
(≤1.5 × ULN) or to baseline, 
then resume brigatinib at same 
dose.
If Grade 3 elevation of lipase 
and amylase recurs, brigatinib 
should be withheld until 
recover y to Grade 1 or less 
(≤1.5 × ULN) or to baseline, 
then resume at the next lower 
dose level per Table 8.a.
Grade 4 (>5.0 × ULN) Withhold brigatinib until 
recover y to Grade 1 or less (less 
than or equal to 1.5 × ULN) or 
to baseline, then resume 
brigatinib at next -lower dose 
(Table 8.a).
If Grade 4 elevation of 
lipase/amy lase recurs, 
permanently discontinue 
brigatinib.
Hyperglycemia Grade 3 (greater than 250 mg/dL or 13.9 
mmol/L) o r greaterIf adequate hyperglycemic control 
cannot be achieved with optimal 
medical management, withhold 
brigatinib until adequate 
hyperglycemic control is achieved 
and consider reduction to the next -
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 38of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTable 8.b Brigatinib Dose Modification Recommendations for Treatment -Related 
Adverse Events
Adverse Reaction Severity* Dose Modification
lower dose ( Table 8.a) or
permanently discontinue brigatinib.
Other Grade 3 Withhold brigatinib until 
recover y to baseline, then 
resume at same dose.
Recurrence: Withhold brigatinib 
until recover y to baseline, then 
resume at next -lower dose or 
discontinue brigatinib
(Table 8.a).
Grade 4 First occurrence: Either 
withhold b rigatinib until 
recover y to baseline and resume 
at next -lower dose ( Table 8.a) or
permanently discontinue.
Permanently discontinue 
brigatinib for recurrence.
Abbreviations: bpm, beats per minute; CPK, creatine phosphokinase; DBP, diastolic blood pressure; HR, heart rate; 
ILD, interstitial lung disease; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse 
Events; SBP, systolic blood pressure; ULN, upper limit of normal.
*Graded per NCI CTCAE, version 4.03.
8.4.2 Pulmonary Adverse Reaction s, Photosensitivity, and Other Adverse Events 
During early clinical development of brigat inib, moderate and severe pulmo nary AEs 
(eg,dyspnea, hypoxia, cough, pneumonia, and pneumonit is) were observed shortly after 
initiation of the drug in a subset of pat ients. These events were termed EOPEs . 
In the ALTA study  (Study  AP26113 -11-201) for bri gatinib, as of 21 February 2017, of 
219treated pati ents, there were 14 cases of EOPE (total 6.4%, 14 of 219). All cases occurred at a 
dose of 90 mg QD. No EOPEs were identified after escalat ion to 180 mg QD in the 90 m g 
QD
→180 m g QD dose group, or after re -initiation following study  treatm ent interruption. 
Median time of EOPE onset was Day  2 (range: 1 -9). Eleven o f these 14 cases were reported as 
serious adverse events (SAEs). Seven patients had events tha t were Grade ≥3, all of who m 
perm anent ly discont inued brigat inib because o f these events. One patient had a Grade 5 EOPE 
(pneumo nia). 
Pulmo nary events occurring within the first 7 day s of treatment, including, but not limited to, 
dyspnea, hypoxia, dry  cough, chest tightness, and presumpt ive lung infect ion (pneumo nia) 
shoul d be m onitored and reported. To reiterate, some events occur after a single dose of 
brigatinib, and physicians should be aware of this possibilit y and discuss it with patients. Newly  
developed or worsening of pulmo nary symptoms in the first week of study  drug administration 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 39of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALspecifically wit h hypoxia and ground glass opac ity on radiographic imaging indicative of ILD or 
pneumo nitis coul d suggest a relat ionship to bri gatinib. Other etio logies, including pulmo nary 
embo lism and infect ious pneumo nia, should be ruled out. If no evidence o f other etio logy is 
ident ified, a causal relati onship to bri gatinib should be considered.
The m anagement of new or worsening pulmo nary symptoms wi thin the first 7 day s of bri gatinib 
treatm ent shoul d include drug interruption, monitoring of oxy gen saturati on, radi ographic 
evaluat ion of the chest, and appropriate workup for infect ious or other etio logy, with high -dose 
corticosteroi ds, supplemental  oxygen therapy , and em piric ant ibiotics as indicated. After drug 
interrupti on and workup of symptoms, if ILD/pneumo nitis is suspected, dose modification 
should be accom plished according to the recommendat ions in Table 8.b. 
Photosensit ivity to sunlight has occurred in pat ients treated with brigatinib. Pa tients shoul d be 
advised to avoid prolonged sun exposure while taking brigat inib, and for at least 5 day s after 
discontinuat ion of treatm ent. When outdoors, patients should be advised to wear a hat and 
protective clothing, and to use a broad -spectrum UVA/U VBsunscreen and lip balm (SPF =30) to 
help protect against potential sunburn. For severe photosensit ivity react ions (≥ Grade 3), 
brigatinib should be withheld unt il recovery to baseline. The dose should be modified according 
to Table 8.b.
See Secti on 6 of the current versio n of the invest igator’s brochure (IB) for detailed informat ion 
on EOPE, late -onset pneumonit is and other AEs, including bradycardia , hypertensi on, visi on 
impairment, blood CPK increased, pancreatic enzymes elevat ion, hyperglycemia and other 
adverse drug reactions observed in the clinical studies with brigat inib.
8.5 Prior and Concomitant Therapies
Anticancer Therapy
History  of prior cance r therapy  will be recorded at screening, and concomitant cancer therapy  
will be recorded during the study  on the appropri ate eCRF for each pat ient. Reasonable efforts 
will be made to collect informat ion on all prior cancer therapy received by the pat ient 
(eg,surgeries, chemotherapy, radiotherapy, immunotherapy, bio logics). The informat ion must be 
obtained fro m the pati ent’s ori ginal source medical document (eg, medical chart for in -hospi tal 
care and medical record for outpatient clinic care) and recorded o n the appropriate eCRF.
Palliat ive therapy and supportive care are permitted during the study for management of 
symptoms and underlying medical condit ions that may develop during the study . Pati ents wi th 
brain lesio ns requiring local radiotherapy such as S RS are allowed to continue study  drug after 
appropriate interruption, as determined by  the investi gator wi th sponsor agreem ent; however, for 
analysis purposes, these patients will be considered to have PD.
New ant icancer therapy  initiated after radio logical PD is observed shall also be co llected in 
eCRF. The informat ion to be collected may including name of the therapy , start and end dates, 
best response, and reason for discont inuat ion. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 40of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALOther Therapy
Concomitant medicat ions for all ongoing medical  history  condi tions or AEs m ust be reported 
from the date the informed consent is signed unt il at least the 30 day s after l ast dose, and for all 
concomitant medicat ions related to serious or study drug -related toxi cities unt il the medicat ion is 
no longer taken or u ntil pat ient contact discontinues.
8.6 Excluded Concomitant Medications and Procedures
Systemic treatm ent wi th the f ollowing medicat ions should be avo ided during the study :
Strong CYP3A inhibitors: boceprevir, clarithro mycin, cobicistat, conivaptan, grapefruit -
containing products including grapefruit juice, idelalisib, indinavir, itraconazole, 
ketoconazo le, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprev ir, 
telithromycin, and voriconazo le. If conco mitant use of a strong CYP3A inhibitor cannot be 
avoided during the study , reduce the brigatinib once daily  dose by approximately  50% 
(ie,from 180 m g to 90 m g, or from  90 m g to 60 m g). After di scont inuat ion of a strong 
CYP3A inhibitor, resume the brigat inib dose that was tolerated before init iating the strong 
CYP3A inhibitor.
Moderate CYP3A inhibitors: aprepitant, cimet idine, ci profl oxacin, cl otrimazole, 
cyclosporine, dilt iazem, dronedarone, ery thromycin, flucon azole, fluvoxamine, imat inib, 
tofisopam , and verapamil. If concomitant use of a moderate CYP3A inhibitor cannot be 
avoided during the study , reduce the brigatinib QD dose by  approximately  40% (i e, from 
180mg to 120 mg, 120 mg to 90 mg, or fro m 90 mg to 60 mg). After discont inuat ion of a 
moderate CYP3A inhibitor, resume the brigatinib dose that was tolerated before init iating the 
moderate CYP3A inhibitor.
Strong CYP3A inducers: carbamazepine, enzalutamide, mitotane, phenobarbital, phenyto in, 
primidone, rifa mpin, rifapent ine, rifabutin, and St. John’s wort.
Moderate CYP3A inducers: bosentan, efavirenz, etravirine, modafinil, and nafcillin.
As the above lists are not exhaust ive, the invest igator should consult the prescribing informat ion 
for any  medicat ion und er considerat ion for use to assess if it is a strong CYP3A inhibitor, 
moderate CYP3A inhibitor, strong CYP3A inducer, or moderate CYP3A inducer. 
The fo llowing m edicat ions and procedures are also prohibited before radio logical disease 
progression is observ ed:
Any illicit substance. Medical use of cannabis is allowed if it is legal where the patient 
resides and no al ternative treatm ent is available, on the base of case -by-case review and 
agreem ent by  the medical  monitor. 
Any other systemic ant icancer therap y including, but not limited to: chemotherapeutic 
agents, immunotherapy , biological response m odifiers (excluding growth factors), 
radiotherapy , and/or systemic hormonal therapy (with the exception of local therapies, such 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 41of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALas SRS, used for palliat ive or sy mptom atic control of exist ing lesio ns, wi th appropri ate 
treatm ent interruption at the discret ion of the investigator).
Use of any  other invest igational drug or device.
8.7 Permitted Concomitant Medications and Procedures
Palliat ive therapy and supportive care are permitted during the study  for m anagement of 
symptoms and underlying medical condit ions that may develop during the study . This may  
include blood and blood products and growth factors as clinically needed. 
8.8 Precautions and Restrictions
Brigatinib induces CYP3A in vi tro and m ay decrease concentrations of CYP3A substrates. 
Coadministration of brigat inib wit h CYP3A substrates, including hormonal contraceptives, can 
resul t in decreased concentrations and loss of efficacy  of CYP3A substrates. Brigat inib may also 
induce other enzymes and transporters (eg, CYP2C, Pgp) via the same mechanism responsible 
for induct ion of CYP3A (eg, pregnane X receptor activat ion). Therefore, addit ional monitoring 
shoul d be considered for patients receiving substrates of these enz ymes and transporters with a 
narrow therapeutic index during treatment with brigatinib as their effect iveness may be reduced.
Brigatinib is an in vitro inhibitor of P -glycoprotein (Pgp), breast cancer resistance protein 
(BCRP), organic cat ion transporter 1 (OCT1), multidrug and toxin extrusion protein 1 (MATE1) 
and 2K (MATE2K). Patients should be closely mo nitored when brigatinib is coadministered with 
substrates of these transporters w ith a narrow therapeutic index (eg, digoxin, dabigatran, 
methotrexate) as their plasma concentrations may  be increased.
8.8.1 Pregnancy, Breastfeeding, and Contraception
It is not known what effects brigat inib has on human pregnancy  or devel opment of the embry oor 
fetus. Therefore, female pat ients participating in this study  shoul d avoi d beco ming pregnant, and 
male pat ients should avo id impregnat ing a female partner. Nonsterilized female pat ients of 
reproducti ve age group and male patients should use effect ive methods of contraception through 
defined periods during and after study  treatment as specified below.
There are no data regarding the secret ion of brigat inib in human milk or its effects on the 
breast fed infant or milk production. Because of the potential f or adverse react ions in breastfed 
infants, female pat ients should not breastfeed during treatment with brigat inib and for 1 week 
following the final dose.
Female pat ients must m eet 1 of  the fo llowing:
Postmenopausal  for at l east 1 year before the screening visit, or
Surgically sterile, or
If they  are of  childbearing potential, agree to practice 1 highly effect ive nonhormonal method 
(see list below) and 1 additional effect ive (barrier) method of contraception at the same time, 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 42of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALfrom the time of signing of the informed consent form (ICF) through at least 4 months after 
the last dose of study  drug, or 
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the pati ent, f rom the time of signing of the ICF through at leas t 4 m onths after the last dose of 
study  drug. (Peri odic abst inence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condom s shoul d not be used together.)
Highly effect ive nonhormonal contraceptive methods suitable for patients taking brigat inib 
include:
intrauterine device.
bilateral  tubal  occl usion.
vasectomised partner.
Because of the potential for genotoxicit y, advise mal es with female partners of reproductive 
potenti al to use effect ive contraception during treatment with brigatinib and after the final dose 
for the durati on specified in the protocol.
Male patients, even if surgically  sterilized (ie, status postvasectomy) must agree to 1 of the 
following:
Agree to practice effective barrier contraception from the time of signing of the ICF through 
at least 4 m onths after the last dose of study  drug, or
Agree to practice true abstinence, when this is in line wit h the preferr ed and usual lifest yle of 
the pati ent, f rom the time of signing of the ICF through at least 4 months after the last dose of 
study  drug. (Peri odic abst inence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
8.9 Blinding and Unblinding
This is an open -label study .
8.10 Description of Investigational Agents
Brigatinib drug product is supplied as film -coated tablets, which may contain 30 mg, 90 mg, or 
180 m g of brigat inib act ive pharmaceut ical ingredient. Brigat inib drug product is recommended 
for storage bel ow 30°C. Do not refrigerate or freeze.
8.11 Packaging and Labeling
Brigatinib drug product will be s upplied as film -coated tabl ets, containing 30 mg, 90 mg, or 
180mg o f brigatinib act ive pharmaceut ical ingredient. Other ingredients will include t ypical 
pharmaceut ical excipients (lactose monohydrate, microcrystalline cellulo se, sodi um starch 
glyco late, colloidal silicon dioxide, and magnesium stearate). The tablet coating is co mposed of 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 43of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALtypical pharm aceut ical grade coating co mponents (talc, propylene glyco l, polyvinyl alcohol , and 
titanium  dioxide). The drug product is manufactured under current Good Manu facturing Practice 
in accordance wit h approved procedures. Brigat inib will be supplied in white high -densit y 
polyethylene bottles with induct ion sealed caps or blister packs. Bottle or blister pack labels will 
bear the appropriate label text as required by governing regul atory  agencies. At a minimum, such 
text will include product name, product strength, number of tablets, and lot number.
8.12 Storage, Handling, and Accountability
Store brigatinibat controlled room temperature 20°C to 25°C with excursio ns permi tted between 
15°C to 30°C.
The invest igator is responsible for ensuring that the study drug provided to the patient and 
returned from the patient are reconciled and noted in source documentation.
All used bottles or blister packs of study  drug m ust be returned to the study  sponsor or destroyed 
in an appropri ate m anner according to the standard practice at each study  center. Destructi on of  
such supplies will be documented, and a representative of the sponsor will verify disposit ion 
records.
During the st udy and at terminat ion, pati ents m ust return all unused study  drug supplies and the 
return of these unused study  drug supplies must be recorded. Returned supplies must not be 
redispensed.
No other use of brigat inib intended for use in this study  is authori zed by  the sponsor. The 
principal investigator or his/her designee will be responsible for the appropriate handling and 
disposi tion of  residual study  drug. Each si te is responsible for proper and careful destruction of 
study  drug returned by patients.
Periodically , throughout and at the conclusio n of the study , a representative of the sponsor will 
conduct an inventory  of unused study  drug. At the complet ion of the study , a final  study  drug 
accountabilit y review will be conducted. Any  discrepancies must be i nvestigated and all unused 
study  drug m ust be destroy ed on si te per the standard operating procedures of the invest igative 
site.
8.13 Other Protocol -Specified Materials
Details are provided in study  manual.
9.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol , Good Clinical Pract ice (GCP), 
applicable regulatory  requi rements, and Internat ional Conference on Harmonisat ion (ICH) 
guidelines.
9.1 Study Personnel and Organizations
The contact informat ion for the proj ect clinician for this study , the central  laboratory  and any 
additional clinical  laboratories, the coordinat ing investigator for each member state/country , and 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 44of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALany addit ional vendors m ay be found in the study  manual. A full list of invest igators is available 
in the sponsor’s investigator d atabase.
9.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for this study may include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruit ment strat egy, they will be reviewed by the IRB/IEC. 
9.3 Treatment Group Assignments
This is a single arm study . All pat ients will be assigned to receive the same treatment.
9.4 Study Procedures
Refer to the Schedules of Events ( Appendix A) for timing of assessments, including those for all 
patients, and for patients receive 240 mg brigat inib. Addit ional details are provided as necessary  
in the sect ions that fo llow.
Sites will make every  effort to see pati ents in the clinic to complete all study -specified 
assessments as outlined in the Schedule of Events (SOE) ( Appendix A). 
In unavo idable circumstances, such as during the COVID -19 public healt h emergency , 
exceptions can be made for alternat ive methods for conducting patient visits and performing 
laboratory  and imaging assessments. Remote visits may  be perform ed via tel eheal th or 
telemedicine as a safet y check on subject well -being. Remote visit s and tel emedicine or 
teleheal th must com ply wit h Takeda processes and local health authorit ies. This will be recorded 
in the eCRF and in the study  records.
In extenuating circumstances, suc h as during the COVID -19 public healt h emergency, local 
laboratory  resul ts and imaging assessment m ay be used. Assessments that cannot be completed 
during the protocol -specified window will be considered missing data, and such departures will 
be recorded i n the study  records. Missed clinic visits or subject withdrawals due to COVID -19 
must be recorded in the protocol deviat ion report and eCRF, as applicable.
9.4.1 Informed Consent
Each patient must provide written informed consent before any  study -requi red proced ures are 
conducted, unless those procedures are performed as part of the patient’s standard care.
Before init iation of the DTP process, pat ients will agree to participate in this process as described 
in Section 8.1.
9.4.2 Patient Demographics
The date of birth (outside European Economic Area) or age (European Economic Area), race, 
ethnicit y (opti onal depending on country ), and sex of the pati ent are to be r ecorded during 
screening.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 45of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL9.4.3 Screening
Screening assessments must be performed no more than 14 day s before Day  1 (the day  of the 
first dose). Whenever feasible, baseline imaging should be performed as close as possible to 
Cycle 1 Day  1. Tum or radi ological  imaging generated for the purpose of regular medical practice 
before patients sign the ICF can be used as baseline disease assessment provided the imaging 
meets the qualit y and time window required for this study . 
Visit Window
The day  the first dose of briga tinib is administered is defined as Day  1. Foll owing visi t may be 
arranged ±3 days fro m the Day  1 of each cycle, with the exception of disease assessment, which 
can be arranged wit h a ±7 -day window. Once radiol ogical disease progression is observed or 
patients have started a new systemic anticancer therapy , the survival fo llow-up shall be arranged 
with a ±14 -day window.
Vital signs shoul d be repeated on Cy cle 1 Day  1 bef ore fi rst dose, regardless of the time from 
screening. Insulin, testosterone (male pat ients) and pregnancy  tests (for female with child-
bearing potential) do not need to be repeated on Day  1 if they were performed for screening 
within 7 days before Day  1, and in the opinio n of the invest igator, there is no rea son to believe 
they have substant ially changed. Physical examination, ECOG performance status assessments, 
hematol ogy, and chemistry  assessments do not need to be repeated on Day  1 if they were 
perform ed for screening wi thin 3 days before Day  1 and, in the opinion o f the invest igator, there 
is no reason to believe they  have substant ially changed. The pregnancy  test m ay be repeated at 
any time during the study  if the pati ent or the investi gator has cause to believe that the patient 
may be pregnant. If screen ing laboratory  assessments need to be repeated on Cycle 1 Day  1, they  
shoul d be obtained before starting treatment.
9.4.4 Enrollment
Patients are consi dered enrolled once the ICF is signed. Patients who signed ICF but did not start 
study  treatm ent will be counte d as screening failure. The reason for screening failure shall be 
docum ented cl early  in the source document and the eCRF. Procedures for complet ion of the 
enrollment informat ion are described in the study  manual.
9.4.5 Medical History
A co mplete medical history , including cancerous and noncancerous disease, will be collected at 
the screening. The ty pe (systemic, surgery , radi otherapy ) and intent (neoadjuvant, adjuvant, 
palliat ive) of prior anticancer therapy to the ALK+ NSCLC, and particularly, the drugs used for
prior systemic ant icancer therapy, the start and end date of each of them and the best response, 
shall be captured in the eCRF. The method that ALK+ status was tested shall also be recorded.
Diagnosis and Cancer History
The init ial cancer di agnosis, ri sk factors (such as tobacco and alcoho l intake), and the current 
cancer stage at the time of screening, along wit h tumor histology  and all sites of disease, should 
be recorded. The American Jo int Committee on Cancer) 7th edition staging 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 46of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL(https://www.sciencedi rect.com /science/arti cle/pii/S1359634907700186) will be ut ilized for 
clinical stage at study  entry . Any previously  identified mutations other than ALK, and the dates 
of identificat ion, must be recorded.
Prior Cancer Therapy
Prior cancer therapy  history  will be taken at screening and includes cancer -related surgi cal 
procedures, radiat ion, and systemic therapies. Surgical procedures include curative and 
palliat ive, as well as diagnostic procedures (eg, biopsy). Radiation will include both definit ive 
and palli ative treatment. Systemic therapy should include all regimens given, type of regimen 
(eg, neo -adjuvant, adjuvant, for advanced or metastatic disease), number of cycles administered 
for each regimen, each drug name in a regimen, the start and stop dates of each drug, the best 
response to the regimen, and the reason for discontinuat ion. Experimental or invest igational 
therapy  for cancer m ust al so be recorded.
ALK Mutati on Status
Regarding current and past ALK mutation history , any previ ously  identified mutations, and the 
dates of ident ificat ion, must be recorded at screening. This includes ALK rearrangements by 
FISH and other methods including immunohistochemistry , and ALK rearrangements and point 
mutati ons by  Next Generat ion Sequencing.
Patients enterin g the study  must ei ther have a history  of a posi tive results fro m FDA -approved 
tests. Otherwise, they  must have a history  of ALK-positivity by another test and submit tissue 
samples for central laboratory  analysis using an FDA -approved test, al though confi rmed ALK -
positivity by a central  laboratory  is not requi red before enro llment. Specifications regarding 
handling and processing of tissue for this test are described in Section 9.4.18.2 and in the study 
manual.
In addit ion, concomitant medicat ions will be recorded as specified in Sect ion 9.4.9 .
9.4.6 Physical Examination
A co mplete physical examinat ion must be performed at screening, the extent of which shoul d be 
consistent with medical history  and the pati ents’ underlying di sease. Subsequent physical 
examinat ions as described in the Schedules of Eve nts (Appendix A) may be di rected to rel evant 
findings. Of note, because o f adverse reactions reported during treatment with brigatinib, 
investigators a re cautioned to monitor patients for signs of visio n dysfunct ion. For new or 
worsening severe visio n disorders, an oph thalmo logical evaluat ion shoul d be perform ed.
The end -of-treatm ent physical examinat ion shoul d be a complete physical examinat ion. The 
30-days - after-last-dose physical examinat ion may be directed to any  relevant findings.
9.4.7 Patient Height and Weight
Height will be measured only during screening. Weight will be measured during screening and at 
every scheduled visit. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 47of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL9.4.8 Vital Signs
Vital signs will include tem perature, pulse, respiratory  rate, and blood pressure (when pat ient is 
seated). Vi tal signs shoul d be repeated on Cycle 1 Day  1, before fi rst dose, regardl ess of the time 
from screening. Vital signs will also be assessed per the Schedules of E vents ( Appendix A).
9.4.9 Concomitant Medications and Procedures
Medicat ions used by the pat ient and therapeutic procedures completed by the pat ient will be 
recorded in the eCRF fro m the time informed consent is signed through 30 days after last dose. 
See Secti on 8.6and Section 8.7for a list of medications and therapies that are prohibited and/or 
allowed du ring the study  treatm ent. 
After 30 day s from last dose, follow -up anticancer treatment for the ALK+ NSCLC shall be 
collected during the survival fo llow-up stage, with the except ion of study  drug bri gatinib being 
used beyo nd radio logical progressi on. Study drug brigatinib used in these cases, at original or 
increased dose, shall cont inue to be reported in study medicat ion sect ion in the eCRF. 
In case brigat inib is prescribed again for regular medical pract ice after study drug brigat inib is 
perm anent ly disc ontinued, this prescribed brigat inib shall be recorded as fo llow-up ant icancer 
treatm ent. 
9.4.10 AEs
Moni toring of AEs, serious and nonserious, will be conducted throughout the study  as specified 
in the Schedules of Events 
(Appendix A). Ref er to Secti on10.0 for details regarding definit ions, 
docum entat ion, and reporting of pretreatment events (PTEs), AEs, and SAEs.
9.4.11 ECG
A 12 -lead ECG will be administered at the time points specified in the Schedules of Events 
(Appendix A).
All ECGs must be 12 -lead ECGs and will be assessed per the Schedules of Events throughout the 
study . The Cycle 1 Day  1 ECG shoul d be performed before the first dose of brigat inib.
Addit ional ECGs may be performed at the invest igator’s discretion to ensure patient safet y. In 
particular, ECG m onitoring shoul d be perform ed during the study  if a pati ent has, during the 
study , been prescribed medicat ion that can prolong the QT interval o r medicat ion that can 
potenti ally alter the QT interval (other than medications explicit ly prohibi ted). For consistency, 
the Fridericia correcti on (QTcF = QT interval/(RR)1/3 interval) method must be used for all 
calculat ions of heart rate -corrected QT (ca lculated) intervals.
9.4.12 Clinical Laboratory Evaluations
Clinical laboratory  testing for safet y evaluations will  be perform ed locally  whenever possible; an 
external laboratory  may be used if necessary . Clinical  laboratory  evaluat ions will be performed 
as outlined in Table 9.a. The frequenc iesof the l aboratory  testsare defined in the Schedules of
Events ( Appendix A). The resul ts shall be recorded in eCRF. The attending physicians may  order 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 48of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALadditional tests as clinically  indicated to follow up on AEs observed during the study . These 
additional results shall  also be captured in the eCRF. However, other tests for the purpose of 
regul ar clinical practice outside of the scope of safety  surveillance for brigat inib will not be 
requi red to enter in the eCRF. The blood sample for Cycle 1 Day  1 clinical la boratory  
assessments should be drawn before the first dose of brigat inib. If the screening blood sample for 
hematol ogy and chemistry  was collected wi thin 3 days of the first dose and, in the opinio n of the 
investigator, there is no reason to believe that t here may be substant ial changes, these tests do not 
need to be repeated on Day  1. If  the insulin, testosterone (for males only), and pregnancy test (for 
females wit h child -bearing potential) were performed within 7 days before Day  1 and, in the 
opinio n of the invest igator, there is no reason to believe that there may be substant ial changes or 
that the patient could be pregnant, these assessments do not need to be repeated on Day 1. If the 
tests need to be repeated, the investigator should review the results before instructing the patients 
to take the first dose of brigat inib.
Table 9.a Clinical Chemistry and Hematology Tests
Hematology Serum Chemistry
Hematocrit
Hemoglobin
Leukocytes with 
differential
Neutrophils (ANC)
Platelet (count)Albumin
ALP
ALT
Amylase
AST
Bilirubin (total)
CalciumCPK
Creatinine 
Chloride
GlucoseLDH
Lipase
Insulin
Magnesium Phosphate
Potassium
Sodium
Testosterone (males)
Abbreviations: ANC, absolute neutrophil count; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; CPK, creatine phosphokinase; LDH, lactate dehydrogenase.
9.4.13 Pregnancy Test
The pregnancy test must be a beta- human chorionic gonadotropin test, and either urine or serum 
can be used. Wo men who are not of childbearing potential (status posthy sterectomy, status 
post-bilateral oophorectomy, or postmenopausal [defined as amenorrhea f or at l east 12 m onths]) 
and men do not need to have the test performed. The test must be known to be negat ive before 
the study  drug administration and be performed within 7 day s before the first dose of brigatinib 
(Cycle 1 Day  1). Wom en of childbearing pot ential at study  start m ust al so com plete the 
pregnancy test once every  3 cycles thereafter and at the end -of-treatm ent visi t. Addi tional 
pregnancy testing should be performed if reco mmended or required per local guidelines or 
regul ations.
9.4.14 Disease Assessmen t
Tumor response assessments will be determined per RECIST version 1.1 by  the invest igator and 
an independent radio logical review.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 49of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAt screening, disease assessment must include imaging of the chest and abdo men (covering 
adrenal glands) using appropriate ra diological procedures (computed tom ography  [CT] scans or 
magnet ic resonance imaging [MRI] with contrast medium, unless contraindicated). MRI of the 
brain enhanced by contrast medium (eg, gadolinium) is required at screening for all pat ients. If 
such m edium for MRI is contraindicated, use CT with contrast medium. All radiographic images 
(eg, CT, MRI) performed during the study  will be submitted to the imaging core laboratory  for 
central  review. Pati ents m ust have at least 1 measurable lesio n per RECIST versi on 1.1. 
Previously  irradiated l esions may  not be used for target lesio ns, unless there is unambiguous 
radiological  progressi on after radi otherapy . Brain lesio ns may be used as target lesio ns provided 
they are ≥10mm and have not been: 1) previously treated with who le brain radiation therapy 
within 3 m onths, or 2) previously treated by  SRS or surgi cal resecti on.
Disease assessment by  CT and MRI scans will be performed at screening and at 8- week intervals 
thereafter (on Day  28 [±7 days] of every  even-numbered cycle) through 14 cy cles after the init ial 
dose of brigat inib, and every 3 cycles (12 weeks) thereafter unt il radio logical  disease progressi on 
is observed. Imaging of chest, abdomen, andbrain will occur at each assessment for allpatients. 
Addit ional tum or assessment can be performed at any time, if clinically  indicated; confirmat ion 
of CR or PR shall be performed at least 4 weeks after init ial response is observed. The same 
imaging modalit y at the same inst itution shoul d be used at each assessment, if po ssible.
For pati ents who conti nue study  treatm ent at the same dose bey ond documented PD per RECIST 
versio n 1.1, at the invest igator’s discret ion and with the sponsor’s medical mo nitor approval , the 
sponsor does not require further tumor assessment to be co llected. The tumor evaluat ion shall be 
managed according to local medical pract ice. 
If pat ients discont inue study  treatm ent due to reasons other than disease progression, tumor 
assessment according to the protocol is strongly encouraged to be continued un til radi ological 
disease progressi on is observed. 
For pati ents who conti nue the study  treatm ent at 240 m g QD bey ond docum ented PD per 
RECIST version 1.1, at the investigator’s discret ion and with the sponsor’s medical mo nitor 
approval , imaging will contin ue wi th the same assessment schedule ( Appendix A). If the patient 
experiences symptomatic deterioration in the absence o f radiologic progression, it i s strongly 
recommended that addit ional imaging studies be performed to confirm PD. 
The disease assessment that documents progression will serve as the new baseline for the dose 
escalat ion to 240 mg QD portion of the study . The investigator will reevaluate the patient for 
target and nontarget lesio ns, according to RECIST criteria, on the basis o f the disease assessment 
scans showing the init ial progressio n. The patient need not repeat imaging assessments before 
dose escalat ion unless the disease assessment is incom plete or occurred >21 days before the first 
dose of brigat inib 240 mg QD, in which case disease assessments must be repeated and will 
serve as the new baseline. If the disease assessment is inco mplete, the site will obtain any  
missing radiographic imaging (eg, MRI of the brain) before dose escalation to 240 mg QD. 
Disease assessment by  CT and MRI scans will be performed at 8 -week intervals thereafter (on 
Day 28 [±7 day s] of every  even -numbered cycle) for 14 cy cles after the init ial dose of brigat inib 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 50of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALat 240 m g QD, and every  3 cycles (12 weeks, ±7 days) thereafter until radiological disease 
progression is observed, according to the new baseline. The same imaging modalit y at the same 
institution shoul d be used at each assessment.
All patients will be followed for radi ological disease progression. For patients who discont inue 
the study  drug for a reason other than object ive disease progression, addit ional tumor assessment 
shoul d be docum ented, if available, unt il disease progression or start of another systemic 
anticancer therapy .
9.4.15 End-of-Treatment Visit
The end -of-treatm ent visi t shoul d be perform ed within 2 weeks (14 day s) of the pati ent’s last 
dose of study  drug or the patient/invest igator decisio n to di scont inue study  drug, whi chever 
occurs l ater. Phy sical examinat ions, laboratory  tests (hematol ogy, chemistry , insulin and 
testosterone for males), as outlined in Table 9.a. ECGs m ay be omi tted if they  had been 
previously performed within 2 weeks since the last assessments and if, in the invest igator’s 
judgment, significant change is unlikely. For patients who discont inued the study drug before 
having radio logical progressi on, tum or assessments shall be cont inued according to the schedule 
in Appendix Auntil radio logical progressi on is observed. 
9.4.16 Thirty -Days -After -Last -Dose Visit
The 30- days-after-last-dose assessments must be performed 30 days (±7 days) after the last dose 
of study  drug. Physical examinat ions, laboratory  tests (hem atology, chemistry , insulin and 
testosterone), and ECG can be omitted if the visit occurs wit hin 10 days o f the end -of-treatment 
assessment and there have been no clinically significant findings. Any new systemic anticancer 
therapi es that the pati ent has begun receiving since the end of treatment should be reported at this 
visit. For both the end -of-treatm ent and 30 -days-after-last-dose assessments, informat ion may be 
collected from tests performed for the study or as part of the patient’s routine medical care. If the 
day of last dose i s more than 30 days before the decision to permanent ly discont inue fro m study  
treatm ent is m ade, the end -of-treatm ent visi t and 30 day s after l ast dose vi sit can be combined as 
one visit. If pat ients permanently discont inued study treatment before radio logical disease 
progression is observed, this visit may occur befo re the end- of-treatm ent visi t.
9.4.17 Follow -up Period
The fo llow-up peri od for a pati ent begins after disease progression or patient starts another 
systemic anticancer therapy  and continues unt il patient contact ceases. If a patient discontinues 
study  drug f or reasons other than disease progression and has not y et started another sy stemic 
anticancer therapy , the pati ent shall cont inue to be fo llowed for radi ological  tumor assessment 
and only  enters follow -up phase once the radiological tumor progression is obser ved or another 
systemic anticancer therapy  is started. The fo llow-up assessments (ie, contacting the patient for 
survival and subsequent anticancer therapy ) must be perform ed every  12 weeks (±14 days) after 
the end of treatment for the last study  drug admi nistered. The allowable window for fo llow-up 
assessments is 14 days. All new ant icancer therapies should be reported.  
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 54of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL9.4.22 Health Utilization Data Collection
During the treatment and fo llow-up peri ods indicated in the Schedules of Events ( Appendix A), 
all medical care encounters since the previous collection will be co llected fro m all pat ients, 
regardl ess of the reason for the medical care encounter at the schedule visit of each cycle during 
study  treatm ent, end-of-treatm ent vi sit, and 30 -days-after-last-dose visit. Examples of data to be 
collected are number and duration of medical care encounters such as inpat ient/outpati ent 
admissio ns, ho mecare, and time of work loss.
9.5 Completion of Study Treatment (for Indi vidual Patients)
For the purpose of analysis, patients will be considered to have co mpleted study  treatm ent once 
they have perm anently discont inued brigat inib because of disease progression, intolerance, 
investigator discret ion, or death while on study  treatment. 
For vi sit purposes, the end -of-treatm ent visit occurs at the l ast dose of study  drug or when the 
investigator or the patient decide the patient will receive no further study  drug, whichever occurs 
later. At 30 day s after l ast dose of study  drug, t he patient shall co mplete all posttreatment 
discontinuat ion assessments. If patient has the last dose equals or more than 30 days before the 
decisio n of permanent discont inuat ion from study  treatm ent is m ade, the end -of-treatm ent visi t 
and 30 -days-after-last-dose vi sit can be combined as 1 visit. 
9.6 Completion of Study (for Individual Patients)
All patients who discont inued study  drug shall be followed for survival, regardless of the reason 
for discont inuat ion. The survival fo llow-up will cont inue unt il pat ients die or study  ends. Pati ents 
will be considered to have completed the study  if they died before or were alive at the time of 
data cut. Patients lost to follow -up or who wi thdraw consent before study  com pletion are not 
counted in the number of patients w ho com pleted the study .
9.7 Discontinuation of Treatment With Study Drug
Study  drug m ust be permanent ly discontinued for:
Intol erable toxi city as determined by  the invest igator.
Progression of disease requiring an alternat ive therapy, in the opinio n of the inv estigator. 
Note: At the discret ion of the investigator, treatment of patients with brigatinib may be continued 
at the recommended dose of 180 mg QD, despite investigator- assessed progression per RECIST 
versio n 1.1, if there is st ill potential for clinical benefit. Treatment of patients with brigat inib 
may be escalated to 240 mg QD, despite invest igator -assessed progression per RECIST 
versio n1.1, at the discretion o f the invest igator and if there is st ill potential for clinical benefit. 
Treatment bey ond pr ogressi on or escalation to 240 mg brigatinib dose is allowed. In both 
scenarios, the sponsor’s medical mo nitor shall  be contacted to approve these cases. Patients shall 
sign an addi tional ICF before the treatm ent continues or increases.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 55of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALRequested by  the pa tient. Note: In cases where patients request to discont inue the study drug, 
the invest igator should assess whether this request is due to study drug –related toxi city. This 
election is applicable only if the patients are not having intolerable toxicit y in the 
investigators’ medical judgment. Patients who request to permanent ly discont inue the study  
treatm ent shall cont inue to be followed for tumor assessment and survival, unless pat ients 
withdraw consent to participate in the study . 
Lost to follow -
up.
Per investigator discret ion, it is in the best interest of the patient to discont inue. If the 
investigator’s determinat ion is made on the basis of into lerable toxicit y, the reason of 
discontinuat ion shall be recorded as intolerable toxicit y. In cases where it i s reported that 
patient discont inuat ion is due to investigator discretion, the situation shall be clearly 
docum ented in the source document and sponsor medical mo nitor shall be contacted to 
discuss alternat ive so lutions before the discontinuation decisio n is made.
Significant protocol  deviat ions that will jeopardize safet y surveillance and pose a significant 
threat to the safet y of the pati ent.
Once study  drug has been discont inued, all study  procedures outlined for the end- of-treatment 
visit will be co mpleted as specified in the Schedules of Events ( Appendix A). The primary  
reason for study  drug di scont inuat ion will be recorded on the eCRF.
9.8 Withdrawal of Patients From Study
A pat ient may be wi thdrawn from  the study  for any  of the f ollowing reasons:
Lost to follow -up.
Study  terminated by  sponsor.
Withdrawal consent by  subject.
Com pleted study .
Death.
The consequence of a patient withdrawing consent fro m further treatment and/or follow -up is 
that no new informat ion will be collected from the withdrawn patient and added to the exist ing 
data or any  database. It i s important to be clear what the patient is withdrawing consent from: 
treatm ent, f ollow -up or both. However, every  effort will be made to fo llow all pat ients for safet y. 
Data collected during pat ient consent, however, must be included in the database.
9.9 Study Compliance
Study  drug will be administered or dispensed only  to eligible pat ients under the super visio n of 
the invest igator or ident ified subinvest igator(s). The appropriate study personnel will maintain 
records of study  drug recei pt and di spensing.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 56of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALIn extenuating circumstances, such as during the COVID -19 public healt h emergency, addit ional 
drug supply may be provided to the subjects to cover extended periods between on -site visi ts as 
described in Section 8.1. 
9.10 Overall Survival
After di sease progressi on or starting another sy stemic anticancer therapy , all pat ients will be 
followed for OS till death or study  terminat ion. The survival fo llow-up ca n be conducted by  
remote method (eg, tel ephone call, etc). At each visit, survival status and informat ion about 
subsequent ant icancer therapy (eg, the name, starting and ending t ime and best known response) 
will be co llected. 
If pat ients discont inue study treatm ent due to reasons other than disease progression, tumor 
assessment according to the protocol is strongly encouraged to be continued unt il radio logical 
disease progressi on is observed. 
10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 PTE Definition
A pretreatment event (PTE) is any untoward medical occurrence in a patient who has signed 
inform ed consent to participate in a study  but before administration of any  study  medicati on; it 
does not necessarily  have to have a causal relat ionship wit h study  parti cipat ion.
10.1.2 AE Defin ition
AE m eans any  untoward m edical  occurrence in a pati ent administered a pharmaceut ical product; 
the untoward medical occurrence does not necessarily have a causal relat ionship with this 
treatm ent. An AE can therefore be any unfavorable and unintended si gn (incl uding an abnorm al 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a m edicinal 
(invest igational) product whether or not it is related to the medicinal product. This includes any 
newly occurring event, or a previous con dition that has increased in severit y or frequency  since 
the administration o f study  drug.
An abnormal laboratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or del ay in treatm ent, dose m odificati on, therapeuti c intervent ion, or is 
considered by the investigator to be a clinically significant change from baseline.
Worsening of signs and symptoms of the malignancy  under study  shoul d be reported as AEs in 
the appropriate section of the eCRF. Disease progressio n assessed by m easurem ent of  malignant 
lesions on radi ographs or other methods should not be reported as an AE.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 57of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL10.1.3 AE Severity
The severit y of AEs will be assessed according to the CTCAE versio n 4.03 (see the study  
manual). If the AE is not defined in the CTCAE, the invest igator will determine the severit y of 
the AE on the basis o f the following definit ions:
Mild (Grade 1): The AE is noticeable to the patient but does not interfere with routine 
activit y.
Moderate (Grade 2): The AE interferes wit h routine activit y but responds to symptomat ic 
therapy  or rest.
Severe (Grade 3): The AE significant ly limits the patient’s abilit y to perform routine 
activit ies despite symptomat ic therapy.
Life-Threatening (Grade 4): The patient is at immediate risk of death.
Death (Grade 5): The patient dies as a direct result of the complicat ion or condit ion induced 
by the AE. 
10.1.4 SAE Definition
SAE m eans any untoward medical occurrence that at any  dose:
Results in death.
Is life-threatening. (Refers to an AE in which the patient was at risk of death at the time of 
the event. It does not refer to an event which hypothet ically might have caused death if it 
were m ore severe.)
Requi res inpat ienthospitalization or prolongation of an existing hospitalization. (See 
clarificati onin the paragraph in Sect ion 10.2 on planned hospitalizat ions.)
Results in persistent or significant disability or incapacity . (Disab ility is defined as a 
substant ial disrupt ion of a person’s abilit y to conduct normal life functions.)
Is a congenital anomaly/birth defect .
Is a medically important event . (Refers to an AE that may not result in death, be 
immediately  life-threatening, or r equire hospitalization, but may be considered serious when, 
on the basis of appropriate medical judgment, it may  jeopardize the patient, require medical 
or surgical intervention to prevent 1 of the outcomes listed above, or invo lves suspected 
transmissio n via a medicinal product of an infect ious agent. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsio ns that do not result in inpat ient hospi talizat ion, or the 
development of drug dependency  or drug abuse; any  organism , virus, or infecti ous parti cle 
[eg,prion protein transmitt ing transmissible spongiform encephalopathy], pathogenic or 
nonpathogenic, is considered an infect ious agent.)
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 58of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALIn thi s study , severi ty for each AE, including any  lab abnormalit y, will be determined using the 
NCI CTCAE, versio n 4.03, effect ive date 14 June 2010 [39].Clarification should be m ade 
between an SAE and an AE that is considered severe in intensit y (Grade 3 or 4), because the 
terms serious and severe are NOT synonymous. The general term severe is often used to describe 
the intensit y (severi ty) of a specific event; the event itself, h owever, may  be of relatively  minor 
medical significance (such as a Grade 3 headache). This is NOT the same as serious , which is 
based on patient/event outcome or action criteria described above, and is usually associated with 
events that pose a threat to a patient’s life or abilit y to functi on. A severe AE (Grade 3 or 4) does 
not necessarily need to be considered serious. For example, a white blood cell count of 
1000/mm3to less than 2000 i s considered Grade 3 (severe) but may  not be consi dered seri ous. 
Seriousness (not intensit y) serves as a gui de for defining regulatory  reporting obligations.
10.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by  the pati ent and/or in response to an open question fro m study  
personnel or revealed by  observati on, physical examinat ion, or other diagnostic procedures will 
be recorded on the appropriate page of the eCRF (see Section
 10.3 for the period of observat ion). 
Any clinically  relevant deteri oration in laboratory  assessments or other clinical finding is 
considered an AE. Wh en possible, signs and symptoms indicat ing a commo n underlying 
pathol ogy shoul d be noted as 1 comprehensive event.
Regardless of causalit y, SAEs m ust be reported (see Section 10.3 for the period of observat ion) 
by the investigator to the Takeda Global Pharmacovigilance depart ment or designee wit hin 24 
hours of beco ming aware of the event. This will be done by transmitting an electronic data 
capture ( EDC) SAE report. If transmissio n of an EDC SAE report is not feasible, then a 
facsimile (fax) of the completed Takeda paper- based SAE form will be sent. A sample of the 
paper -based SAE form and processing directions are in the study  manual. Inform ation in the 
SAE report or form must be consistent with the data provided on the eCRF.
If informat ion not available at the time of the first report becomes available at a later date, then 
the invest igator will transmit a fo llow-up EDC SAE report (or a paper -based S AE form if an 
EDC SAE report is not feasible) or provide other documentation immediately wit hin 24 hours of 
recei pt. Copi es of  any relevant data from  the hospital  notes (eg, ECGs, l aboratory  tests, di scharge 
summary, postmortem results) should be sent to t he addressee, if requested.
Planned hospi tal admissio ns or surgical procedures for an illness or disease that existed before 
study  drug was given are not to be considered AEs unless the condit ion deteri orated in an 
unexpected manner during the trial (eg, surgery  was perform ed earlier or l ater than planned).
For both serious and nonserious AEs, the invest igator must determine both the severit y (toxi city 
grade) of the event and the relat ionship of the event to study drug administration. For serious 
PTEs, the invest igator must determine both the severit y (toxi city grade) of the event and the 
causalit y of the event in rel ation to study  procedures.
Severit y (toxi city grade) for each AE, including any  lab abnorm ality, will be determined using 
the NCI CTCAE, versi on4.03, effect ive date 14 June 2010 [39]. The criteria are provided in the 
study  manual .
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 59of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALRelationship of the event to study  drug administrati on (ie, its causa lity) will be determined by  
the invest igator responding yes(related) or no(unrelated) to this quest ion: “Is there a reasonable 
possibilit y that the AE is associated with the study  drug?”
10.3 Monitoring of AEs and Period of Observation
AEs, both nonserious an d seri ous, will  be monitored throughout the study  as fo llows:
AEs will be reported from the signing of informed consent through 30 day s after 
administration of the last dose of study  drug and recorded i n the eCRFs. 
SAEs.
Serious PTEs will be reported to t he Takeda Global Pharmacovigilance department or 
designee fro m the tim e of the si gning of the ICF up to first dose of study  drug, and will also 
be recorded in the eCRF. 
Related and unrelated treatment -emergent SAEs will be reported to the Takeda Global 
Pharmacovigilance department or designee from the first dose of study  drug through 30 days 
after administrati on of  the l ast dose of study  drug and recorded in the eCRF. After this 
period, only  SAEs suspected by  the invest igator to be related to the study tre atment m ust be 
reported to the Takeda Global Pharmacovigilance department or designee. SAEs should be 
monitored until they are resolved or are clearly  determined to be due to a patient’s stable or 
chronic condit ion or intercurrent illness(es).
10.4 Procedures f or Reporting Drug Exposure During Pregnancy and Birth Events
If a woman becomes pregnant or suspects that she is pregnant while participating in this study , 
she m ust inform  the investi gator immediately and permanent ly discont inue study  drug. The 
sponsor m ust al so be contacted immediately by  faxing a com pleted pregnancy  form to the 
Takeda Gl obal Pharmacovigilance depart ment or designee (see Section
 10.2). The pregnancy 
must be fo llowed for the final pregnancy outcome.
If a female partner of a male patient becomes pregnant during the male pat ient’s participat ion in 
this study , the sponsor m ust also be contacted immediately by  faxing a com pleted pregnancy 
form to the Takeda Global Pharmacovigilance department or designee (see Sect ion 10.2). Every  
effort should be made to fo llow the pregnancy  for the final pregnancy  outcom e.
10.5 Procedures for Reporting Product Complaint s or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissat isfaction 
regarding the identit y, strength, puri ty, quali ty, or s tabilit y of a drug product. Individuals who 
ident ify a potent ia
l product com plaint si tuation shoul d immediately report this via the phone 
numbers or email addresses provided below.
A medicat ion error is a preventable event that involves an ident ifiable pat ient and that l eads to 
inappropriate medicat ion use, which ma y resul t in patient harm. Whereas overdoses and 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 60of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALunderdoses const itute medication errors, doses missed inadvertent ly by a pat ient do not. 
Individuals who ident ify a potential medicat ion error (including overdose) situation should 
immediately  report thi s via the phone numbers or email addresses provided below.
Product Call Center Phone Number Email Fax
Brigatinib Dohmen Life 
Science Services1-844-662-8532 
Non–toll-free number: 
1-510-740-1273 GlobalOncologyMedinfo@t
akeda.com1-800-881-6092
Product complaints in and o f themselves are not AEs. If a product complaint results in an SAE, 
the invest igator must report the SAE through EDC (refer to Section 10.2).
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, including the European 
Medicines Agency, invest igators, and IRBs or IECs, as applicable, in accordance wit h nat ional 
regul ations in the countries where the study  is conducted. Relat ive to the first awareness of the 
event by/or further provisio n to the sponsor or sponsor’s designee, SUSARs will be submitted to 
the regulatory  authori ties as an expedited report within 7 day s for fatal  and life -threatening 
events and 15 days for other serious events, unless otherwise required by national regulat ions. 
The sp onsor will also prepare an expedited report for other safet y issues where these might 
materi ally alter the current benefit -risk assessment of an invest igational medicinal product or that 
woul d be sufficient to consider changes in the investigat ional medici nal product’s administrati on 
or in the overall conduct of the trial. The invest igatio nal site also will forward a copy  of all 
expedited reports to his or her IRB or IEC in accordance with national regulat ions. 
11.0 STUDY -SPECIFIC COMMITTEES
11.1 Steering Committee 
A steering committee composed of external medical experts will be organized to provide 
scientific guidance to study  design, conduct ion, and reporting. The details o f the steering 
committee membership and responsibilit ies will be included in the steering c ommittee charter.
11.2 Independent Review Committee
A central  blinded IRC with no knowledge of the patients’ status on study  will evaluate all images 
collected during the study  for the primary  endpoint of confirmed ORR as well as several 
secondary  endpoints. An IRC charter defines the procedures used by  the committee.
Following the primary  analysis, the sponsor reserves the right to discontinue assessment of 
images by the IRC.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 61of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL12.0 DATA HANDLING AND RE CORDKEEPING
The full details o f procedures for data handling will be docum ented in the Data Management 
Plan. If selected for coding, AEs, PTEs, medical history , and concurrent condit ions will be coded 
using the Medical Dict ionary for Regul atory  Activit ies (MedDRA). Drugs will be coded using 
the World Healt h Organizat ion Drug Dict ionary.
12.1 eCRFs 
Com pleted eCRFs are required for each patient who signs an ICF.
The sponsor or its designee will supply invest igative sites with access to eCRFs and will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor, contract 
research organizat ion (CRO) partners, and regulatory  authori ties. Invest igative sites must 
complete eCRFs in English.
After complet ion of t he entry  process, com puter l ogic checks will be run to identify items, such 
as inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site.
Any change of, modificat ionof, or addi tion to the data on the eCRFs should be made by  the 
investigator or appropriate site personnel . Corrections to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion of the person making the 
correcti on, the date the correction was made, and the reason for change.
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the principal invest igator must retain 
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permit ted to review the patient’s medical 
and hospital records pertinent to the study  to ensure accuracy  of the eCRFs. The com pleted 
eCRFs are the sole property  of the sponsor and should not be made available in any  form to thi rd 
parties, except for authorized r epresentatives of appropriate governmental health or regulatory  
authorities, wi thout wri tten permissio n of the sponsor.
In extenuating circumstances, such as during the COVID -19 public healt h emergency, direct, 
suitably controll ed rem ote access to pati ents’ electroni c medical  records may  be used for data 
monitoring. Only pseudonymized documents may be shared through a cloud -based system. 
Videoconferencing may  be used for rem ote si te data verificat ion, but copying or recording of the 
video and/or documents ( eg, screen captures) is not permitted. These procedures will be 
docum ented in the Monitoring Plan. 
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 62of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALparticipat ing patients, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated ICFs, subject authorization forms regarding the use of 
personal healt h informat ion (if separate from the ICFs), electronic copy  of eCRFs, including the 
audit trail , and detailed records of drug disposit ion to enable e valuat ions or audits fro m 
regul atory  authori ties, the sponsor or its designees. Any  source docum entati on printed on 
degradable thermal sensit ive paper should be photocopied by the site and filed with the original 
in the pat ient’s chart to ensure long term legibilit y. Furtherm ore, ICH E6 Section 4.9.5 requires 
the invest igator to retain essent ial documents specified in ICH E6 (Section 8) until at least 
2years after the last approval of a market ing application for a specified drug indicat ion being 
investigat ed or, if an applicat ion is not approved, unt il at least 2 years after the invest igation is 
discontinued and regulatory  authori ties are notified. In addit ion, ICH E6 Secti on4.9.5 states that 
the study  records should be retained unt il an amount of time spe cified by  applicable regul atory  
requi rements or for a time specified in the clinical study  site agreement between the investigator 
and sponsor.
Refer to the clinical study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of 
any such documents.
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A SAP will be prepared and finalized before database lock. This document will provide further 
details regarding the definit ion of analysis variables and analysis methodology  to address all 
study  object ives.
The final analysis o f the primary  endpoint (confirmed ORR) will be conducted approximately 
6months after the last patient is enro lled. The confirmed O RR will be tested at a one -sided alpha 
of 0.025. 
13.1.1 Analysis Sets
13.1.1.1 Full Analysis Set
All patients who receive at least one dose of brigatinib will be included in the full analysis set. 
Primary analyses of safet y and efficacy will be performed using the full a nalysis set.
13.1.1.2 Per-Protocol Population
The per -protocol populat ion will exclude all pat ients in the full analysis set who do not meet key  
entry  criteria, have no m easurable disease at baseline, or have no adequate postbaseline response 
assessment unless the reason i s death or early discontinuat ion due to disease progression. In 
particular, pati ents who have no history  of an ALK rearrangement by  an FDA approved test at 
study  entry  and whose protocol -mandated central test is negat ive for an ALK rearrangement wi ll 
be excluded fro m the per -protocol analysis.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 63of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALFurther criteria for the per -protocol population and the sensit ivity analyses of the primary  
endpo int and selected secondary  efficacy  endpoints using this population will be detailed in the 
SAP.
13.1.2 Analysis of De mographics and Other Baseline Characteristics
Dem ographics and baseline characterist ics will be summarized using descript ive statist ics. 
Continuous variables will be summarized by means, medians, standard deviat ions, and ranges; 
categori cal variables will be summarized by counts and percentages. Other variables may also be 
included in this analysis by categorizing the continuous variables or recategorizing exist ing 
categori cal variables.
13.1.3 Efficacy Analysis
13.1.3.1 Definitions of Efficacy Endpoints
The primary  endpoint (confirmed ORR assessed by the IRC) is defined as the proportion of the 
patients who are confirmed to have achieved CR or PR, per RECIST versio n 1.1 (confirmed 
≥4weeks after init ial response), out of all pat ients who have had at least one dose of study  drug 
(the full analysis set). 
Secondary  efficacy endpo ints for this study  are defined as fo llows:
Confirmed ORR assessed by the invest igator is defined as the proportion of the patients who 
are confirmed to have achieved CR or PR per in vestigator using RECIST version 1.1 after 
the init iation of study  treatm ent in the full analysis set.
DOR i s defined as the time interval from the time that the measurement criteria are first met 
for CR/PR (whichever is first recorded) until the first date that the PD i s object ively 
docum ented, or death in pat ients with a confirmed response.
PFS i s defined as the time interval from the date of the first dose of the study  treatm ent until 
the first date at which radio logical disease progressio n is object ively docum ented, or death 
due to any  cause, whichever occurs first, in the full analysis set. PFS will be censored for 
patients wi thout documented disease progression or death.
Disease control  rate is defined as the proportion of patients who have achieved CR, PR, or 
SD (in the case of SD, measurements must have met the SD criteria at least once after study  
entry  at a minimum interval of 6 weeks) after the init iation of study  treatm ent.
Time to response is defined as the time interval from the date of the first dose of the study  
treatm ent until the init ial observation o f CR or PR.
Confirmed iORR is defined as the proportion of the patients who have achieved CR or PR in 
the brain per a modificat ion of RECIST versio n 1.1, after the init iation of study  treatm ent, i n 
patients wi th intracranial brain metastases at baseline. The criteria of intracranial efficacy 
assessment will be defined in more detail in the SAP. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 64of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALDurati on of  intracranial response is defined as the time interval fro m the time that the 
measurement criteria are first met for CR or PR in the brain (whichever is first recorded) 
until the first date that PD in the brain is objectively documented or death, in patients with 
intracranial  metastases at baseline.
iPFS is defined as the time interval from the date of the first dose of the study  treatm ent until 
the first date at which intracranial brain disease progression is object ively documented, or 
death due to any  cause, whichever occurs first, in patients with intracranial metastases at 
enrollment. iPFS w ill be censored for patients without documented intracranial disease 
progression or death. 
OS is defined as the time interval fro m the date of the first dose of the study  treatm ent until 
death due to any  cause in the full analysis set. It will be censored on the date of last contact 
for those pati ents who are alive.
13.1.3.2 Primary Efficacy Endpoint Analyses
The best response (CR, PR, SD, or PD), according to RECIST version 1.1, will be derived for 
each eligible patient who receives at least 1 dose of study treatm ent. The ORR is calculated as 
the proporti on of  patients who are confirmed to have achieved CR or PR after the init iation of 
study  treatm ent. Confirmed responses are those that persist on repeat imaging at least 4 weeks 
after ini tial response. At the final analysis, exact 2 -sided 95% CIs for the ORR will be calculated 
on the basis of the bino mial distribut ion. The primary  analysis will be performed on ORR 
assessed by  the IRC. Best target l esion response will be displayed using a “waterfall” plot. 
Supportive sensi tivity analyses will  be perform ed for ORR assessed by the IRC in the 
per-protocol population. Supportive sensit ivity analyses will also be performed in pat ients 
confirmed to be ALK+ via central assessment and within subgroups defined by age, sex, rac e, 
geographi c regi on, m utation status, pri or anti cancer therapi es, and other prognostic factors. 
Continuous prognostic factors affect ing the ORR may be explored using simple logistic 
regression models.
13.1.3.3 Secondary Efficacy Endpoint Analyses
Confirmed ORR ass essed by the invest igator in the full analysis set and the per -protocol 
popul ation will be analyzed to assess the robustness of the primary analysis o f the primary 
endpo int.
Disease control  rate assessed by the invest igator in the full analysis set and the per-protocol 
popul ation and the exact 2- sided 95% bino mial CIs will be calculated.
For time -to-event efficacy endpo ints (PFS, DOR, OS), median values and 2 -sided 95% CIs will 
be est imated using Kaplan -Meier method [40] in the full analysis set. The PFS rates and OS rates 
at 12 and 24 months and the associated 2- sided 95% CIs will be computed.
Time to response will be summarized only for confirmed responders using descript ive statist ics.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 65of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALIn pati ents wi th CNS m etastases at enrollment , iORR assessed by a separate IRC and the exact 
2-sided 95% bino mial CIs will  be calculated; median intracranial DOR and PFS will be 
estimated using the Kaplan
-Meier method.
13.1.4 Pharmacokinetic Analysis
PK data collected in this study  will contribute to popul ation PK and exposure/response (safet y 
and efficacy ) analyses. These analyses may  include data from  other bri gatinib clinical studies. 
The plans f or these analyses will be developed and the results reported separately.
13.1.5 Subgroup Analysis in Patients Progress ed on Alectinib
If the primary  endpoint is achieved in pat ients previously treated with alect inib or cerit inib, then 
a subgroup analysis of confirmed ORR in pat ients progressed on alect inib will be performed and 
tested at a one -sided alpha o f 0.025.
13.1.6 Analys is of Patient -Reported Outcomes and Health Resource Utilization Data
The analysis will be based on patients with baseline and at least 1 postbaseline measurement. 
The actual  value and change fro m baseline of the summary /subscale scores of EORTC QLQ -C30 
and the subscale scores of EORTC QLQ -LC13 will be summarized using descript ive statist ics 
over time. The number and percentage of patients with improved EORTC QLQ -C30 and 
EORTC QLQ -LC13 scores will also be summarized over time, where improvement will be 
defined on the basis o f change from baseline scores and a published responder definit ion 
thresho ld of 10. Addit ionally, time to QOL deterioration based on EORTC QLQ- C30 and 
EORTC QLQ -LC13 scores will also be analyzed. Time to QOL deterioration will be defined 
from first dosing date to the date of the first occurrence of QOL scores deterioration of more than 
10 fro m baseline. 
Published manuals/guidance for the questionnaires will be used for scoring and handling missing 
data. Further invest igation about missing data and subsequent ly sensit ivity analysis for missing 
data m ay be conducted. 
Com pliance for EORTC QLQ -C30, EORTC QLQ -LC13,  will also be 
summarized over time. 
HU as measured by hospitalizat ions, outpatient visits, and missed days of work or other activit ies 
by patients and caregivers will be summarized using descript ive statist ics.
13.1.7 Safety Analysis
AEs will be summarized using the safet y analysis set. 
Safety assessmen ts will include physical and laboratory  examinat ions, vital signs, and ECGs.
AEs will be graded according to the NCI CTCAE versio n 4.03.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 66of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAll patients who receive at least 1 dose of study  treatm ent will be evaluated for safet y. The 
proporti on of  patients with at least 1 TEAE, TRAE, and serious treatment -emergent adverse 
event (SAE) will be described, as identified wit h preferred terms and MedDRA system organ 
class. The frequency of occurrence of overall toxicit y, categori zed by  the maximum  toxicity 
grades (s everit y), will also be described. List ings of laboratory  test resul ts and CTCAE grades 
will be generated, and descript ive statist ics summari zing the changes in laboratory  tests over 
time will be presented.
Exploratory  analyses will also be performed on oth er safet y param eters, as deem ed appropri ate, 
and wit hin subgroups defined by age, sex, race, mutation status, prior anticancer therapies, 
medical history , and other prognostic factors.
Exposure to study  treatm ent over time will be summarized with t ime on treatm ent, total amount 
of administrated treatment, dose intensit y and rel ative dose intensit y.
Safety will be assessed from the first dose of study treatment for all pat ients and fro m the date of 
escalat ion to 240 mg QD in pat ients who escalate after PD.
13.2 Sample Size Justification
The sample size was determined so that it would allow for stating that the true ORR (expected 
response rate) is greater than the thresho ld response rate of 20% for patients previously treated 
by alect inib or cerit inib. A total of approximately  103 pati ents will be enrolled. This sample size 
was calculated to provide at least 90% power to rule out an uninterest ing ORR of 20%, assuming 
the true ORR is 35%. The calculat ion is based on an exact bino mial test with a total one -sided 
alpha level  of 0.025 at primary  endpoint analysis, allowing for dropout.
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protoco l are followed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or its 
designee (CRO) and by  the IRB or IEC.
All aspects of the study  and i ts docum entati on will be subject to review by the sponsor or 
designee (as long as blinding is not jeopardized), including but not limited to the IB, study  
medicat ion, pati ent m edical records, informed consent documentation, documentation of pat ient 
authori zation to use personal healt h information (if separate from the ICFs), and review of 
eCRFs and associated source documents. It is important that the investigator and other study  
perso nnel are available during the monitoring visit s and that sufficient time is devoted to the 
process.
In extenuating circumstances, such as during the COVID -19 public healt h emergency, direct, 
suitably controll ed rem ote access to patients’ electroni c medical records may  be used for data 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 67of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALmonitoring. Only pseudonymized documents may be shared through a cloud -based system. 
Videoconferencing may  be used for rem ote si te data verificat ion, but copying or recording of the 
video and/or documents (eg, screen captures) is not permitted. These procedures will be 
docum ented in the Monitoring Plan. 
14.2 Protocol Deviations
The sponsor or sponsor delegates cannot grant waiver to the protocol requirement. The 
investigator should not deviate fro m the protocol , except where necess ary to eliminate an 
immediate hazard to study  patients. Shoul d other unexpected circumstances arise that will 
requi re deviat ion from protocol -specified procedures, the invest igator should consult with the 
sponsor or designee (and IRB or IEC, as required) t o determine the appropriate course of act ion. 
There will be no exempt ions (a prospectively approved deviat ion) fro m the inclusion or 
exclusio n criteria.
The site should document all protocol deviat ions in the patient’s source documents. In the event 
of a significant deviation, the site should notify the sponsor or its designee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the patient, or confound inte rpretati on of  primary  study  
assessment. A Protocol Deviat ion Form  shoul d be com pleted by  the si te and signed by the 
sponsor or designee for any  significant deviat ion from the protocol.
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory samples are co llected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that thi s study  may be inspected by  regulatory  agencies, 
including those of foreign governments (eg, th e FDA, the United Kingdo m Medicines and 
Healthcare products Regul atory  Agency , the Pharmaceut icals and Medical Devices Agency o f 
Japan). If the study  site is contacted for an inspection by  a regulatory  body, the sponsor should 
be notified immediately. The invest igator and inst itution guarantee access for qualit y assurance 
auditors to all study  docum ents as described in Section 14.1.
15.0 ETHICAL ASPECTS OF THE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, patients) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guide line for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the responsibilit ies of the invest igator listed in Appendix B.The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 68of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL15.1 Benefit -Risk of the Study
The intended study  popul ation are patients with refractory  disease and those who have limited 
treatm ent opti ons. 
The study  drug bri gatinib will be used at the standard 90 mg to 180 mg dose. The safet y profile 
of brigat inib at thi s dose is well established fro m the previous studies (AP26113 -11-101, 
AP26113 -
13-201, and AP26113 -13-301). The safety  surveillance procedures in this protocol are 
similar to those used in previous brigatinib studies and are reasonable to ensure proper 
monitoring of pat ients’ safet y. A detailed dose modificat ion gui deline is provi ded in this protocol 
in case treatm ent-related toxicit y emerges. Only  patients who tol erated previ ous doses well and 
have disease progression will be offered the opportunit y to esca late to 240 mg, and an addit ional 
ICF will be provided before dose escalat ion. This dose level is st ill below the maximum dose 
studi ed in humans, and the MTD was not reached in a phase 1 study  of brigatinib. Therefore, any  
toxicities are expected to be man ageable. 
The m andatory  procedures requi red by this study are similar to the m anagement that these 
patients will  receive as part of clinical pract ice. 
The data collect ion and reporting plan are standard for such studies. These will ensure the 
collect ion of high-qualit y data to report clinically  meaningful  outcom es. 
Brigatinib may have ant itumor effects in ALK+ metastatic NSCLC pat ients who have already 
progressed on alect inib or cerit inib according to nonclinical studies. Patients enro lled in this 
study  may have clinical benefit from the study  drug bri gatinib. The efficacy and safet y from this 
study  will serve as important evidence to evaluate the use of brigatinib in this populat ion and 
potenti ally benefi t more pati ents in the future. 
In summary, the ben efit-risk of this study  supports the protocol to be implemented. 
15.2 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local 
requi rements of each participating regio n. The sponsor or designee will require docum entati on 
noting all names and tit les of members who make up the respect ive IRB or IEC. If any member 
of the IRB or IEC has direct participat ion in this study , written notificat ion regarding his or her 
abstinence fro m voting must also be obtained. Thos e American sites unwilling to provide names 
and tit les of all members because of privacy and conflict of interest concerns should instead 
provi de a Federal Wide Assurance Number or comparable number assigned by the Department 
of Heal th and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy  of the ICF, and, if 
applicable, patient recruitment materials and/or advert isements and other documents required by 
all applicable laws and regulat ions, m ust be submit ted to a central or local IRB or IEC for 
approval . The IRB’s or IEC’s written approval of the protocol and subject informed consent 
must be obtained and submitted to the sponso r or designee before commencement of the study  
(ie, before shipment of the sponsor -supplied drug or study specific screening act ivity). The IRB 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 69of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALor IEC approval must refer to the study  by exact protocol  title, number, and versio n date; ident ify 
versio ns of other docum ents (eg, ICF) reviewed; and state the approval date. The sponsor will 
ship drug/notify  site once the sponsor has confirmed the adequacy  of site regul atory  
docum entati on and, when applicable, the sponsor has received permissio n from competent 
authority to begin the tri al. Unt il the site receives [drug/notificat ion] no protocol act ivities, 
including screening may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  patients, local safet y reporti ng requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submissio n of the invest igator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the sponsor or its 
designee.
Subject incentives should not exert undue influence for partici pation. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
15.3 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Gui delines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, subject authorizat ion form (if applicable), and subject 
inform ation sheet (if applicable) describe the planned and permitted uses, transfers, and 
disclosures of the subject’s personal and personal healt h informat ion for purposes of conducting 
the study . The ICF and the subject informat ion sheet (if applicable) further explain the nature of 
the study , its obj ectives, and potential risks and benefits, as well as the date informed consent is 
given. The ICF will detail the requirements of the participant and the fact that he or she is free to 
withdraw at any  time wi thout giving a reason and without prejudice to his or her further medical 
care.
The invest igator i s responsible for the preparation, content, and IRB or IEC approval of the ICF 
and if applicable, the subject authorizat ion form. The ICF, subject authorization form (if 
applicable), and subject informat ion sheet (if applicable) must be approved by both the IRB or 
IEC and the sponsor before use.
The ICF, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) 
must be written in a language fully co mprehensible to the prospective subject. It is the 
responsibilit y of th e invest igator to explain the detailed elements of the ICF, subject 
authori zation form (if applicable), and subject info rmation sheet (if applicable) to the subject. 
Inform ation shoul d be given in both oral and written form whenever possible and in the man ner 
deem ed appropri ate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable la ws and regul ations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity  
to: (1) inquire about details of the study  and (2) deci de whether or not to participate in the study . 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 70of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALIf the subject, or the subject’s lega lly acceptable representative, determines he or she will 
participate in the study , then the ICF and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
conse nt and before the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and da te the ICF and subject 
authori zation (if applicable) at the time o f consent and before subject entering into the study; 
however, the sponsor may  allow a designee of the investi gator to si gn to the extent permitted by  
applicable law.
Once signed, the origin al ICF, subject authori zation form (if applicable), and subject informat ion 
sheet (if applicable) will be stored in the investigator’s site file. The investigator must document 
the date the subject signs the informed consent in the subject’s medical record . Copi es of the 
signed ICF, the si gned subject authorizat ion form (if applicable), and subject informat ion sheet 
(if applicable) shall be given to the subject.
All revised ICFs must be reviewed and signed by relevant subjects or the relevant subject’s 
legally acceptable representative in the same manner as the original informed consent. The date 
the revised consent was obtained should be recorded in the subject’s medical record, and the 
subject should receive a copy  of the revised ICF.
15.4 Subject Confidentiali ty
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a uni que i dentificat ion number. As 
permitted by  all applicable laws and regulations, limited subject attributes, such as sex, age, or 
date of birth, and subject init ials may be used to verify the subject and accuracy  of the subject’s 
unique identificat ion number.
To com ply with ICH Gui delines for GCP and to verify compliance with this protocol, the 
sponsor requires the investigator to permit its monitor or designee’s mo nitor, representatives 
from any regulatory  authori ty (eg, FDA, Medicines and Healt hcare p roducts Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laborat ory test result reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study  
participat ion, and autopsy  reports. Access to a subject’s original medical records requires the 
specific authorizat ion of the subject as part of the informed consent process (see Section 15.3).
Copi es of  any subject source documents that are provided to the sponsor must hav e certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s [e]CRF).
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 71of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL15.5 Publication, Disclosure, and Clinical Trial Registration Policy
15.5.1 Publication 
The invest igator is obliged t o provi de the sponsor with complete test results and all data derived 
by the investigator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as re quired by 
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertis ements, is the sole responsibilit y of the sponsor.
The sponsor may publish any  data and informat ion fro m the study  (including data and 
inform ation generated by  the invest igator) without the consent of the invest igator. Manuscript 
authorship for any  peer -reviewed publication will appropriately reflect contribut ions to the 
producti on and review of the document. All publications and presentations must be prepared in 
accordance with this Section and the clinical study site agreement. In the event of any 
discrep ancy between the protocol  and the clinical study  site agreement, the clinical study  site 
agreem ent will prevail.
15.5.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register 
intervent ional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov or other 
publicly  accessible websites on or before start of study , as defined in Takeda Policy /Standard. 
Takeda contact information, alo ng with invest igator’s cit y, state (for Am ericas invest igators), 
country , and recrui ting status will be registered and available for public viewing. 
As needed Takeda and Investigator/site contact information may b e made public to support 
participant access to trials via registries. In certain situations/registries, Takeda may assist 
participants or potential part icipants to find a clinical trial by  helping them  locate tri al sites 
closest to thei r homes by providing the investigator name, address, and phone number via 
email/phone or other methods callers request ing trial informat ion. Once subjects receive 
investigator contact information, they  may call  the si te requesting enrollment into the trial. The 
investigat ive sites are encouraged to handle the trial inquiries according to their established 
subject screening process. If the caller asks addit ional quest ions beyo nd the topic of trial 
enrollment, they should be referred to the sponsor.
Any invest igator who objects to Takeda providing this informat ion to callers must provide 
Takeda wi th a wri tten noti ce request ing that their informat ion not be listed on the registry  site. 
15.5.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trials on ClinicalT rials.gov or other publicly  accessible 
websites (including the Takeda corporate site) and registries, as required by Takeda 
Policy/Standard, applicable laws and/or regulations. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 72of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALData Sharing
The sponsor is committed to responsible sharing of clinical data with the goal  of advancing 
medical science and improving pat ient care. Qualified independent researchers will be permitted 
to use data collected from pat ients during the study to conduct additional scient ific research, 
which may  be unrelated to the study  drug or the patient’s disease. The data provided to external 
researchers will not include informat ion that i dentifies pat ients personally.
15.6 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulat ions applicable to the 
site where the subject is participat ing. If a local underwriter is required, then the sponsor or 
sponsor’s designee will obtain clinical study  insurance against the risk of injury  to clinical  study  
subjects. Refer to the clinical study  site agreement regarding the sponsor’s policy  on subject 
compensat ion and treatment for injury . If the investi gator has quest ions regarding this policy, he 
or she should contact the sponsor or sponsor’s designee.
16.0 REFERENCES
1. Ferlay  J, Ste liarova -Foucher E, Lortet -Tieulent J, Rosso S, Coebergh JW, Comber H, et al. 
Cancer incidence and mortalit y patterns in Europe: estimates for 40 countries in 2012. 
European Journal of Cancer 2013;49(6):1374-403.
2. Jemal A, Bray  F, Center MM, Ferlay J, War d E, Form an D. Gl obal cancer statistics. CA 
Cancer J Clin 2011;61(2):69 -90.
3. American Cancer Societ y. Cancer Facts & Figures. CA: A Cancer Journal for Clinicians 
2018.
4. Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, Grimsrud TK, et al. 
Survival patterns in lung and pleural cancer in Europe 1999 -2007: Results fro m the 
EUROCARE -5 study . Eur J Cancer 2015;51(15):2242-53.
5. Howl ader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer 
Statistics Review, 1975- 2013. Nati onal Cancer Insti tute 2016.
6. NCCN Clinical Pract ice Guidelines in Onco logy: Sm all Cell Lung Cancer versio n 2.2013. 
National Com prehensive Cancer Network. 2013.
7. Reck M, Popat S, Reinmuth N, De Ruy sscher D, Kerr KM, Peters S, et al. Metastatic non-
small -cell l ung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, 
treatm ent and follow -up. Ann Oncol  2014;25 Suppl 3:iii27-39.
8. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non -small cell  lung cancer: 
epidemi ology, risk f actors, treatm ent, and survivorship. May o Clin Proc 2008;83(5):584 -
94.
9. Camidge DR, Doebele RC. Treating ALK -positive lung cancer --early successes and future 
challenges. Nature Reviews Clinical Onco logy 2012;9(5):268 -77.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 73of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL10. Soda M, Choi YL, Eno moto M, Takada S, Yamashi ta Y, Ishikawa S, et al . Ident ificat ion of 
the transforming EML4- ALK fusion gene in non -small -cell lung cancer. Nature 
2007;448(7153):561-6.
11. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of 
phosphoty rosine signaling ident ifies oncogenic kinases in lung cancer. Cell 
2007;131(6):1190 -203.
12. Takeuchi K, Cho i YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B -ALK, a 
novel fusio n oncokinase identified by an immunohistochemistry -based diagnost ic system 
for ALK -positive lung cancer. Clin Cancer Res 2009;15(9):3143 -9.
13. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomo n B, Maki RG, et al. Anaplastic 
lympho ma kinase inhibit ion in non-small -cell lung cancer. N Engl  J Med 
2010;363(18):1693 -703.
14. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4 -ALK 
fusio n gene is invo lved in various histologic ty pes of  lung cancers fro m nonsmokers wit h 
wild-type EGFR and KRAS. Cancer 2009;115(8):1723 -33.
15. XALKORI (crizotinib) [prescribing informat ion]. New York, NY, USA: Pf izer Labs, 
March 2016.
16. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First -line crizotinib 
versus chemotherapy  in ALK -positive lung cancer. N Engl  J Med 2014;371(23):2167-77.
17. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Kata yama R, et al . ALK 
rearrangements are mutually exclusive wit h mutations in EGFR or KRAS: an analysis of 
1,683 patients with non -small cell lung cancer. Clin Cancer Res 2013;19(15):4273-81.
18. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplas tic lympho ma kinase in 
lung cancer: a paradigm for precisio n cancer medicine. Clin Cancer Res 2015;21(10):2227-
35.
19. Toyokawa G, Inamasu E, Shimamatsu S, Yoshida T, Nosaki K, Hirai F, et al. Ident ificat ion 
of a Novel  ALK G1123S Mutati on in a Pati ent wi thALK -rearranged Non -small-cell Lung 
Cancer Exhibit ing Resistance to Cerit inib. J Thorac Onco l 2015;10(7):e55-7.
20. Costa DB, Kobay ashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of 
the anaplast ic lympho ma kinase inhibitor crizotinib. Jo urnal of Clinical Onco logy 
2011;29(15):e443 -5.
21. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Jr., et al. Local ablative 
therapy  of oligoprogressive disease prolongs disease control by t yrosine kinase inhibitors in 
oncogene -addicted non -smal l-cell lung cancer. J Thorac Oncol 2012;7(12):1807 -14.
22. ZYKADIA (cerit inib) [prescribing informat ion]. East Hanover, NJ, USA: Novartis 
Pharmaceut icals Corporation, 6/2017.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 74of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL23. ALECENSA (alectinib) [prescribing informat ion]. South San Francisco, CA: Gene ntech 
USA, Inc., November 2017.
24. Soria JC, Tan DSW, Chiari R, Wu YL, Paz -Ares L, Wolf J, et al. First -line cerit inib versus 
platinum -based chemotherapy  in advanced ALK -rearranged non -small -cell lung cancer 
(ASCEND- 4): a randomised, open -label, phase 3 s tudy. Lancet 2017;389(10072):917 -29.
25. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alect inib versus 
crizotinib in patients with ALK -positive non -small -cell lung cancer (J- ALEX): an open -
label, rando mised phase 3 trial. Lancet 2017;390(10 089):29 -39.
26. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alect inib versus 
Crizotinib in Untreated ALK -Positive Non -Small-Cell Lung Cancer. N Engl J Med 
2017;377(9):829 -38.
27. Friboulet L, Li N, Katay ama R, Lee CC, Gainor JF, Cry stal AS, et al. The ALK inhibitor 
ceritinib overco mes crizotinib resistance in non -small  cell lung cancer. Cancer Discovery  
2014;4(6):662 -73.
28. Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, et al. I1171 missense 
mutati on (parti cularly I1171N) is a commo n resistance mutation in ALK -positive NSCLC 
patients who have progressive disease while on alectinib and is sensit ive to ceritinib. Lung 
Cancer 2015;88(2):231 -4.
29. Ou S, Azada M, Hsiang D, Herman J, Kain T, Siwak -Tapp C, et al. Next -generat ion 
sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R 
mutati on confers high -level resistance to al ectinib (CH5424802/RO5424802) in ALK-
rearranged NSCLC pat ients who progressed on crizotinib. J Thorac Onco l 2014;9(4):549 -
53.
30. Tchek medyian N, Ali SM, Miller VA, Haura EB. Acquired ALK L1152R Mutation 
Confers Resistance to Ceritinib and Predicts Response to Alect inib. J Thorac Onco l 
2016;11(7):e87-8.
31. Shaw A, Peters S, Mok T. Alect inib versus crizotinib in treatm ent-naive advanced ALK -
positive non-small  cell lung cancer (NSCLC): Primary  resul ts of the gl obal phase III ALEX 
study . J Clin Oncol  2017;35(suppl; abstr 9006).
32. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or
Platinum -Pemetrexed in EGFR T790M -Positive Lung Cancer. N Engl J Med 
2017;376(7):629 -40.
33. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katay ama R, et al . Molecular 
Mechanisms o f Resistance to First -and Second -Generat ion ALK Inhibitors in A LK-
Rearranged Lung Cancer. Cancer Discov 2016;6(10):1118-33.
34. Carbone DP, Reck M, Paz -Ares L, Creelan B, Horn L, Steins M, et al. First -Line 
Nivo lumab in Stage IV or Recurrent Non -Small-Cell Lung Cancer. N Engl J Med 
2017;376(25):2415 -26.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 75of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIAL35. Zhang S, A njum R, Squillace R, Nadworny  S, Zhou T, Keats J, et al. The Potent ALK 
Inhibitor Brigatinib (AP26113) Overcomes Mechanisms o f Resistance to First -and 
Second- Generat ion ALK Inhibitors in Preclinical Models. Clin Cancer Res 
2016;22(22):5527 -38.
36. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alect inib in 
Crizotinib -Refractory  ALK-Rearranged Non -Small-Cell Lung Cancer: A Phase II Global 
Study . Journal  of Clinical  Oncol ogy 2016;34(7):661 -8.
37. Novello S, Mazières J, Oh I, De Castro J, M igliorino M, Helland A, et al. Primary  resul ts 
from the Phase III ALUR study  of alect inib versus chemotherapy in previously treated 
ALK+ non -small -cell lung cancer (NSCLC). ESMO Congress; Madrid.
38. Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, et al . Mul ticenter Phase II 
Study  of Whole -Body  and Intracranial Act ivity With Cerit inib in Pat ients Wit h ALK -
Rearranged Non- Small-Cell Lung Cancer Previously  Treated Wi th Chem otherapy  and 
Crizotinib: Results From ASCEND -2. J Clin Oncol 2016;34(24):286 6-73.
39. Commo n Termino logy Criteria f or Adverse Events (CTCAE). National Cancer Inst itute, 
National Inst itutes of Healt h, U.S. Department of Health and Human Services Series v4.03. 
June 14, 2010. Publicat ion No. 09 -
5410.
40. Kaplan E, Meier P. Nonparametric est imation from incomplete observat ions. Journal  of the 
American Statistical Association 1958;53:457 -81.
41. Levey  AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using 
standardized serum creat inine values in the modificati on of  diet in renal  disease study  
equati on for estimat ing glo merular filtrat ion rate. Ann Intern Med 2006;145(4):247 -54.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 76of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAppendix ASchedules of Events
Schedule of Events: Study Assessments for All Patients
Screening 
Period Treatment Through 30 Days After Last DoseFollow -up 
Period
Assessment Screening Cycle 1 aEvery Cycle 
(Starting at 
Cycle 2)Cycle 3 
Day 1 and 
Cycle 5 
Day 1Every
2 Cycles 
(From 
Cycle 2 to 
Cycle 14)Every
3 Cycles 
After 
Cycle 14End of 
Treatment b30 Days 
After Last 
Dose bFollow -up c
Day D -14 to D0 D1 D8 D15 D1 D1 D28 D28
Informed consent (main) X
Demographics X
Medical/surgical history X
Diagnosis and cancer 
historyX
Prior cancer therapy dX
Prior ALK+ test report 
including test method e X
Physical examination X X X X X X X
Vital signs X X X X X X X
ECOG performance 
statusX X X X X X
Hematology X fX fX X X X X
Chemistry X fX fX X X X X
Insulin gX fX fX X X X
Testosterone level (men 
only) X fX fX X X
ECG X X X X X
AEs Throughout study h
Concomitant 
medicationsUntil last dose i
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 77of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALScreening 
Period Treatment Through 30 Days After Last DoseFollow -up 
Period
Assessment Screening Cycle 1 aEvery Cycle 
(Starting at 
Cycle 2)Cycle 3 
Day 1 and 
Cycle 5 
Day 1Every
2 Cycles 
(From 
Cycle 2 to 
Cycle 14)Every
3 Cycles 
After 
Cycle 14End of 
Treatment b30 Days 
After Last 
Dose bFollow -up c
Day D -14 to D0 D1 D8 D15 D1 D1 D28 D28
Pregnancy test (women 
with child bearing 
potential) jX X X
Disease assessment X pX kX kX
Plasma sample for 
brigatinib PK Refer to Appendix A, PK Sampling Schedule
Archival (banked) tumor 
tissue sample X l
Optional tumor tissue 
rebiopsy sample X lX m, q
Plasma sample for 
ctDNAX X X m, q
PRO assessment 
(EORTC QLQ -C30 and 
QLQ -LC-13)X X X X X
HU assessment X X X X
Subsequent anticancer 
therapy /survival o X
AEs, adverse events; ALK+, anaplastic lymphoma kinase positive; C, Cycle; ctDNA, circulating tumor DNA; D, Day; ECG, electroc ardiogram; ECOG, Eastern Cooperative 
Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; HU, health resource utility; NSCLC, non –small -cell lung cancer; PK, 
pharmacokinetics; PRO, patient -reported outcomes; QD, once daily. 
a1 cycle = 28 days. The allowed visit day window is ±3 days, starting from Cycle 2, with the exception of disease assessment.
bThis visit shall be scheduled with a ±7 -day window. If patient has the last dose equals or more than 30 days before the decision of permanent discontinuation from st udy 
treatment is made, the end -of-treatment visit and 30 days after last dose visit can be com bined as one visit.
c Survival follow -up shall be scheduled with a ±14 -day window.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 78of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALScreening 
Period Treatment Through 30 Days After Last DoseFollow -up 
Period
Assessment Screening Cycle 1 aEvery Cycle 
(Starting at 
Cycle 2)Cycle 3 
Day 1 and 
Cycle 5 
Day 1Every
2 Cycles 
(From 
Cycle 2 to 
Cycle 14)Every
3 Cycles 
After 
Cycle 14End of 
Treatment b30 Days 
After Last 
Dose bFollow -up c
Day D -14 to D0 D1 D8 D15 D1 D1 D28 D28
dThe prior cancer therapy need sto include the detail of prior treatment, starting and ending time, and the best response to each treatment. 
e The assay and sample type of prior ALK test will also be collected.
fIf the blood tests are performed within 3 days of first dose, the Cycle 1 Day 1 tests are not required to be repeated, unless clinically indicated. 
gGlucose and insulin will be tested concurrently.
hAssessment f or early pulmonary symptoms must be performed during the visit on Day 8. The AEs and SAEs will be reported from the signing o f informed consent through 
30days after administration of the last dose of study drug. After this period, only SAEs suspected by t he investigator to be related to the study treatment must be reported.
iConcomitant medications must be reported from the time informed consent is signed until at least the 30 -days-after-last-dose assessment, and for all concomitant medications 
related to serious or study drug -related toxicities until the medication is no longer taken or until patient contact discontinues. After study drug is discont inued, only new anticancer 
therapy  to the ALK+ NSCLC need to be reported.
jPregnancy test must be known to be negative before the study drug administration and be performed within 7 days before the fi rst dose of brigatinib (Cycle 1 Day 1) and should 
be repeated every 3rd cycle on treatment (ie, C3D1, C6D1, etc).
kEvery 8 weeks ±7 days for 14 cycles, then every 3 cycles (12 weeks) ±7 days. Imaging of chest, abdomen and brain will occur at each assessment for all patients until disease 
progression is observed. If patients continue to receive the study drug beyond progression, the tumor assessment will be managed according to local clinical practice and no need 
to be collected in eCRF. If a patient discontinues study drug for reasons other than disease progression and has not yet star ted another systemic anticancer therapy, the pati ent 
shall continue to be followed for radiological tumor assessment and only enters follow -up phase once the radiological tumor progression is observed or another systemic 
anticancer therapy is started.
l Archival tumor sample from recent biopsy after pati ent progresses on alectinib or ceritinib is highly encouraged. If the original ALK+ was not tested by an FDA -approved 
method, then archived or fresh tumor tissue is mandatory.
mFor patients who dose escalate to 240 mg QD, the end -of-treatment, 30 -days-after-last-dose, and follow -up assessments will not be performed until after the last dose of 
brigatinib at 240 mg QD. Dose escalation to 240 mg QD can proceed immediately following medical monitor approval with adheren ce to the Schedule of Events for treatme nt 
continuation at 240 mg QD after progression on the following page.
  
oThis refers to other anticancer therapy after brigatinib is discontinued.
p Tumor radiological imaging used as baseline disease assessment before ICF was signed is allowed to be used if they were generated through patien ts' regular 
medical care and within the required window.
q If study treatment is stopped for a reason other than disease progressio n, the re -biopsy and ctDNA shall be collected after confirmed disease progression occurs. If study 
treatment is continued beyond progression, the re -biopsy and ctDNA shall only be collected at the initial progression. They are not required to be repeated o nce these patients 
further progress and stop the treatment entirely.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 79of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALSchedule of Events –Treatment Continuation at 240 mg QD After Progression
Treatment Through 30 Days After Last DoseFollow -up 
Period
AssessmentBefore 
Dose 
Escalation
(14 Days) aEscalation
Cycle 1 bEvery 
Escalation
Cycle 
(Starting at 
Cycle 2)Cycle 3 
Day 1 and 
Cycle 5 
Day 1Every 2 
Escalation 
Cycles c (From 
Escalation Cycle 
2 to Cycle 14)Every 3 
Escalation
Cycles after 
Escalation 
Cycle 14End of 
Treatment30 Days 
After Last 
Dose Follow -up
Day D1 dD1 D15 D1
Informed consent 
to 240 mgX
Physical 
examinationX X X X X X
Vital signs X X X X X X
ECOG 
performance statusX X X X X X
Hematology X eX eX X X X
Chemistry X eX eX X X X
Insulin fX eX eX X X
Testosterone level 
(men only)X eX eX X X
ECG X X X X X
AEs Throughout study
Concomitant 
medicationsUntil last dose g
Pregnancy test hX X X
Disease 
assessmentX cX cX
Plasma sample for 
brigatinib PKRefer to Appendix A, PK Sampling Schedule
Plasma sample for 
ctDNAX X Xj
Optional tumor 
tissue rebiopsyX X I, j
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 80of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTreatment Through 30 Days After Last DoseFollow -up 
Period
AssessmentBefore 
Dose 
Escalation
(14 Days) aEscalation
Cycle 1 bEvery 
Escalation
Cycle 
(Starting at 
Cycle 2)Cycle 3 
Day 1 and 
Cycle 5 
Day 1Every 2 
Escalation 
Cycles c (From 
Escalation Cycle 
2 to Cycle 14)Every 3 
Escalation
Cycles after 
Escalation 
Cycle 14End of 
Treatment30 Days 
After Last 
Dose Follow -up
Day D1 dD1 D15 D1
sample at disease 
progression
PRO assessment X X X X X
HU assessment X
Subsequent 
anticancer 
therapy /survivalX
Abbreviations: AEs, adverse events; ALK+, anaplastic lymphoma kinase -positive; C, Cycle; ctDNA, circulating tumor DNA; D, Day; ECG, electrocardiogram; ECOG, Eastern 
Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; HU, health resource utility; N SCLC, non –small -cell lung cancer; PK, 
pharmacokinetics; PRO, p atient -reported outcomes; QD, once daily.
aLast visit on 180 mg QD can be used as rebaseline assessment before dose escalation.
b 1 cycle = 28 days.
cEvery 8 weeks ±7 days for 14 cycles, then every 3 cycles(12 weeks) ±7 days. Imaging of chest, abdomen a nd brain will occur at each assessment for all patients until disease 
progression is observed. If patients continue to receive the study drug beyond progression, the tumor assessment will be mana ged according to local clinical practice and no need to 
be co llected in eCRF.
dPerformed before first dose at 240 mg QD. The week and day listed in this table are counted from the first day of 240 mg dose .
eIf the blood tests are performed within 3 days of first dose, the Cycle 1 Day 1 tests are not required to be repeated, unless clinically indicated.
fGlucose and insulin will be tested concurrently.
gConcomitant medications must be reported from the time informed consent is signed until at least the 30 -days
-after-last-dose assessment, and for all concomitant me dications 
related to serious or study drug -related toxicities until the medication is no longer taken or until patient contact discontinues. After study drug is discont inued, only new anticancer 
therapy  to the ALK+ NSCLC need to be reported.
hPregnancy te st should be repeated every 3rd cycle on treatment (ie, C3D1, C6D1, etc).
iAt disease progression.
JIf study treatment is stopped for a reason other than disease progression, the re -biopsy and ctDNA shall be collected after confirmed disease progression occurs. If study treatment 
is continued beyond progression, the re -biopsy and ctDNA shall only be collected at the initial progression; they are not required to be repeated once these patients further progress 
and stop the treatment entirely.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 81of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALPK Sampling Schedule
Upon implementation o f Amendment 5, no further PK sample co llection will be performed as all ongoing patients have completed at 
least 5 cy cles of treatm ent.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 82of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAll Patients
The PK samples outlined in the schedule below are to be collected in all patients.
PK Sampling TimeCycle 1
Day 1Cycle 1
Day 8Cycle 2
Day 1Cycle 3
Day 1Cycle 4
Day 1Cycle 5
Day 1
Predose (within 4 h before dosing) X X X X X
1 h postdose (±15 min) X X X
4 h postdose (±30 min) X X X
PK, pharmacokinetics.
For Patients Receiving 240 mg Brigatinib Postprogression
The PK samples outlined in the schedule below are to be collected in patients who receive the 240 mg brigat inib dose postprogression.
PK Sampling Time aCycle 1
Day 1Cycle 2
Day 1Cycle 3
Day 1Cycl e 4
Day 1Cycle 5
Day 1
Predose (within 4 h before dosing) X X X X X
1 h postdose (±15 min) X
4 h postdose (±30 min) X
PK, pharmacokinetics.
aCycle and day listed in this table are counted from the first day of the 240 mg brigatinib dose.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 83of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAppendix B Responsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which m ust be completed and 
signed before the invest igator may participate in this study. 
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572: 
Conduct the study  in accordance wit h the protocol. 1.
Personally conduct or supervise the staff who will assist in the protocol. 2.
Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 3.
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed 4.
of these obligat ions.
Secure prior approval of the study  and any  changes by  an appropri ate IRB/IEC that conform 5.
to 21 CFR Part 56 ICH, and local regulatory requirements.
Ensure that the IRB/IEC will be responsible for initial review, continuing review, and 6.
approval  of the protocol . Prom ptly report to the IRB/IEC all changes in research act ivity and 
all anticipated ri sks to subj ects. Make at l east y early  reports on the progress of the study  to 
the IRB/IEC, and issue a final report within 3 mo nths of study  com pletion.
Ensure that requirements for informed consent, as outlined in 21 CFR Part 50 ICH and local 7.
regul ations, are met.
Obta in valid informed consent from each subject who participates in the study, and document 8.
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each ICF should contain a subject author ization Section 
that describes the uses and disclo sures of a subject’s personal information (including personal 
healt h informat ion) that will take place in connect ion with the study . If an ICF does not 
include such a subject authorization, then the investi gator m ust obtain a separate subject 
authori zation form from each subject or the subject’s legally  acceptable representative.
Prepare and maintain adequate case histories of all persons entered into the study , incl uding 9.
eCRFs, hospital records, laboratory resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 10.
docum ents.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 84of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALMaintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 11.
drugs, and return all unused sponsor -supplied drugs to the sponsor .
Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 12.
within 24 hours.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 85of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAppendix CInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transfer red to other parties located in countries throughout the world (eg, the 
United Kingdom, US, and Japan), including the fo llowing:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissi on of regul atory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to other medications use d in other clinical studies that may 
contain the same chemical compound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and l icensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in investigator’s 
own country .
Invest igator acknowledges and consents to the use of his or her personal information by Take da 
and other parties for the purposes described above.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 86of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAppendix DEastern Cooperative Oncology Group Scale for Performance Status
Grade Description
0 Normal activity. Fully active, able to carry on all predisease performance without restriction.
1 Symptoms but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to 
carry  out work of a light or sedentary nature (eg, light housework, office work).
2 In bed <50% of the time. Ambulatory and capable of all self -care, but unable to carry out any work 
activities. Up and about more than 50% of waking hours.
3 In bed >50% of the time. Capable of only limited self -care, confined to bed or chair more than 50% 
of waking hours.
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair.
5 Dead
Source: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response 
criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;5(6):649 -55.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 87of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAppendix EResponse Evaluation Criteria In Solid T umors (RECIST Version 1.1)
Note: These criteria are adapted from Eisenhauer EA, Therasse P, Bogaerts J, et al. New 
response evaluat ion criteria in so lid tumours: Revised RECIST guideline (versio n 1.1). Eu J 
Cancer 2009;45:228 - 247.
Choosing Target Lesions
Select up to 5 lesions (up to 2 per organ).
Select largest reproducibly  measurable lesio ns.
If the largest lesio n cannot be measured reproducibly, select the next largest lesion which can 
be.
Add up l ongest di ameters (LD) of non -nodal  lesions (axial  plane).
Add short axis diameters of nodes.
This is the sum of the longest diameters (SLD).
Nontarget Lesions
All other sites of disease present at baseline and not classified as target lesio ns will be 
classified as nontarget lesions, including any measurable lesions that were not chosen as 
target lesio ns.
It is possible to record mult iple nontarget lesio ns involving the same organ as a single item 
on the eCRF (eg, “mult iple enlarged pelvic lymph nodes”).
Determining Response
Assess at baseline and on study  with consistent modalit ies (CT, MRI, PET/CT).
–Measure target lesio ns and calculate SLD.
–Visually assess nontarget lesio ns.
–Search for new lesio ns.
–Combine these assessments into the overall response.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 88of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALTarget Lesion Response
Complete response (CR) Disappearance of all extranodal target lesions.
All pathological lymph nodes must have decreased to <10 mm in short 
axis.
Partial response (PR) At least a 30% decrease in the SLD of target lesions, taking as reference 
the baseline sum diameters.
Progress ive disease (PD) SLD increased by at least 20% from the smallest value on study 
(including baseline, if that is the smallest).
SLD must also demonstrate an absolute increase of at least 5 mm. (2 
lesions increasing from, for example, 2 mm to 3 mm, does not qualify ).
Stable disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify  for PD.
Nonevaluable (NE) One or more lesions cannot be evaluated because of missing data or poor 
image quality unless a convincing argument can be made that the 
contribution of the individual missing lesion(s) would not change the 
assigned time point response (eg, PD based on other findings).
SLD, sum of the longest diameters.
Nontarget Lesion Response
Complete response (CR) Disappearance of all extranodal nontarget lesions.
All ly mph nodes must be nonpathological in size (<10 mm short axis).
Normalization of tumor marker level.
Non-CR/no n-PD Persistence of 1 or more nontarget lesions(s) and/or maintenance of 
tumor marker level above the nor mal limits.
Progressive disease (PD) Unequivocal progression of existing nontarget lesions (subjective 
judgment by experienced reader).
Unable to evaluate (UE) One or more lesions cannot be evaluated because of missing data or poor 
image quality unless a convincing argument can be made that the 
contribution of the individual missing lesion(s) would not change the 
assigned time point response (eg, PD based on other findings).
New Lesions 
Shoul d be unequivocal and not attributable to differences in scann ing technique or findings 
which may  not be a tum or (does not have to meet criteria to be “measurable”). 
If a new lesio n is equivocal, continue to next time point. If confirmed then, PD is assessed at 
the date when the lesio n was first seen. 
Lesio ns identified in anatomic locations not scanned at baseline are considered new. 
New l esions on ul trasound shoul d be confirmed on CT or MRI.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 89of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALEvaluation of Overall Time Point Response for Patients With Measurable Disease at 
Baseline
Target Lesions Nontarget Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/no n-PD No PR
CR NE No PR
PR Non-PD or NE No PR
SD Non-PD or NE No SD
Not all evaluated Non-PD No NE
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease; NE, nonevaluable.
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 90of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAppendix FModification of Diet in Renal Disease Equation for Estimated Glomerular 
Filtration Rate 
The fo llowing i s the isotope dilut ion mass spectrometry  (IDMS) -traceable Modificat ion of Diet 
in Renal disease (MDRD) equation (for creatinine methods calibrated to an IDMS reference 
method): 
GFR (mL/min/1.73 m2) = 175 × (S cr)-1.154× (Age)-0.203× (0.742 if female) × (1. 212 if 
African American)
GFR, glomerular filtration rate; S cr, serum creatinine. 
Levey et al, 2006 [41]. 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 91of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAppen dix GProtocol History
Date Amendment Number Type Region
12 February 2021 5 Substantial Global
24 September 2020 4 Substantial Global
27 September 2019 3 Substantial Global
10 April 2019 2 Substantial Global
11 December 2018 1 DE v1 Nonsubstantial Germany
12 October 2018 1 SE v1 Nonsubstantial Sweden
03 May  2018 1 Nonsubstantial Global
22 February 2018 Initial Protocol Not applicable Global
Amendment 4
The primary  reasons for thi s amendment are to m aintain patient safet y, confident iality, and study  
integrity in the context of healt hcare challenges presented by  the coronavirus disease 2019 
(COVID -19) public health emergency. This amendment allows invest igators  and study  personnel 
to conduct visit s rem otely , deliver study  drug di rectly  to pati ents, use l ocal laboratory  and 
imaging results if patients are unable to travel to the invest igative site, and remotely access 
patient records for data monitoring as n ecessary  during the COVID -19 public healt h emergency. 
Secondly, the dose modificat ion for Grade 3 and 4 creatine phosphokinase (CPK) elevat ions 
without concurrent muscular toxicit y was deemed no longer warranted.
Protocol Amendment 4
Summary of Changes Since the Last Version of the Approved Protocol
Section(s) Affected by 
Change Description of Each Change and Rationale
Location(s) Description Rationale
Section 8.1
Study Drug 
AdministrationAdded text: In extenuating 
circumstances, such as during the 
COVID -19 public health emergency, 
additional drug supply may be provided 
to the subjects to cover periods between 
on-site visits. Additional study drug may 
be dispensed during a scheduled study 
visit, o r study drug may be shipped 
directly from investigational sites to 
participants’ residences by a contracted 
logistics provider or distributor (direct -
to-patient [DTP] shipment) in agreement 
with Takeda processes and local health 
autho rities. 
Before initiation of the DTP process, 
patients will agree to participate in this 
process. Patients will sign a separate To maintain patient safety, confidentiality, 
and study integrity in the context of 
healthcare challenges p resented by the 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 92of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALProtocol Amendment 4
Summary of Changes Since the Last Version of the Approved Protocol
Section(s) Affected by 
Change Description of Each Change and Rationale
Location(s) Description Rationale
acknowledgment of receipt form 
permitting this process and agree to 
share limited personal information with 
the delivery courier. The investigator 
and co urier must ensure that no private 
patient information is shared with the 
sponsor or other CROs participating in 
the study . The local independent review 
board (IRB)/independent ethics 
committee (IEC) must be notified, as 
applicable per local requirements, t hat 
this process is being initiated, and sites 
must clearly document the chain of 
custody of any study drug dispensed 
directly to patients. COVID -19 public health emergency. This 
amendment allows investigators and study 
personnel to conduct visits remotely, deliver 
study drug directly to patients, and to use 
local laboratory and imaging results if 
patients are unable to travel to the 
investigative site.
Section 9.4 
Study ProceduresAdded text: Sites will make ever y effort 
to see patients in the clinic to complete 
all study -specified assessments as 
outlined in the Schedule of Events 
(SOE) (Appendix A). In unavoidable 
circumstances, such as during the 
COVID -19 public health emergency, 
exceptions can be made for alternative 
methods for conducting patient visits 
and performing laboratory and imaging 
assessments. Remote visits may be 
performed via telehealth or telemedicine 
as a safety check on subject well -being. 
Rem ote visits and telemedicine or 
telehealth must comply with Takeda 
processes and local health authorities. 
This will be recorded in the eCRF and in 
the study  records.
In extenuating circumstances, such as 
during the COVID -19 public health 
emergency, local laboratory results and 
imaging ass essment may be used. 
Assessments that cannot be completed 
during the protocol -specified window 
will be considered missing data, and 
such departures will be recorded in the 
study records. Missed clinic visits or 
subject withdrawals due to COVID -19 
must be r ecorded in the protocol 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 93of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALProtocol Amendment 4
Summary of Changes Since the Last Version of the Approved Protocol
Section(s) Affected by 
Change Description of Each Change and Rationale
Location(s) Description Rationale
deviation report and eCRF, as 
applicable.
Section 9.4.1
Informed ConsentAdded text: Before initiation of the DTP 
process, patients will agree to participate 
in this process as described in Section 
8.1.
Section 9.8 
Study ComplianceAdded text: In extenuating 
circumstances, such as during the 
COVID -19 public health emergency, 
additional drug supply may be provided 
to the subjects to cover extended periods 
between on -site visits as described in 
Section 8.1.
Section 12.1 eC RFs
Section 14.1 Study -Site 
Monitoring Visits In extenuating circumstances, such as 
during the COVID -19 public health 
emergency, direct, suitably controlled 
remote access to patients’ electronic 
medical records may be used for data 
monitoring. Only pseudo nymized 
documents may be shared through a 
cloud -based system. Videoconferencing 
may be used for remote site data 
verification, but copying or recording of 
the video and/or documents (eg, screen 
captures) is not permitted. These 
procedures will be documented in the 
Monitoring Plan. 
Table 8.b Revised:
Grade 4 CPK elevation (greater than 
10.0 × ULN) or recurrence of Grade 3 
elevation 
• Withhold brigatinib until recover y to 
Grade 1 or less (less than or equal to 2.5 
× ULN) or to baseline, then resume 
brigatinib at next -lower dose (Table 8.a).
• If Grade 4 elevation of CPK recurs, 
permanently discontinue brigatinib.The dose modifications for Grade 4 CPK 
elevation or recurrence of Grade 3 CPK 
elevation were changed to align with the 
Company Core Data Sheet. A n analy sis of 
data from Studies AP26113-13-301 and 
AP26113 -13-201 suggested that CPK 
increases were associated with longer 
duration of treatment and did not seem to be 
associated with the frequency of muscular 
toxicity. In a review of individual patient 
data from these studies, only 1 patient 
reported a Grade 3 CPK elevation as well as 
a Grade 3 muscular toxicity (PT: muscular 
toxicity). Additionally, many of the 49 
patients from these studies with a Grade ≥3 
CPK elevation did not report a muscular 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 94of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALProtocol Amendment 4
Summary of Changes Since the Last Version of the Approved Protocol
Section(s) Affected by 
Change Description of Each Change and Rationale
Location(s) Description Rationale
toxicity event (any  grade o r Grade ≥3). 
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 95of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAmendment 3 
Rationale for Amendment 3
The primary  reason for thi s amendment is to remove the interim analysis. 
Addit ional changes were made for consistency wit hin the protocol and for clarit y. Minor 
grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of the 
study  are included for cl arificati on purposes only . 
Changes in Amendment 03
1.Removed interim  analysis. 
2.Clarified that the endpoint analyses will be perfo rmed using the full analysis set. 
Amendment 2
Rationale for Amendment 2
The primary  reason for thi s amendment is to update the fo llowing dose modificat ion tables for 
consistency wit h the Company Core Data Sheet (CCDS) for brigat inib and provide clarit y on
allowed dose levels:
Table 8.a Recommended Brigat inib Dose Reduct ion Levels.
Table 8.b Brigat inib Dose Modificat ion Reco mmendat ions for Treatm ent-Related Adverse 
Events.
Addit ional changes were made for consistency wit hin the protocol and for clarit y. Min or 
grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of the 
study  are included for cl arificati on purposes only .
Changes in Amendment 2
Update primary object ive in the Study  Summary  (Secti on 2.0) for consistency with p rimary 1.
objective in main protocol (Section 5.1.1).
Delete the redundant Sample Size Just ification row fro m the Study  Summary  (Secti on 2.0). 2.
Revise Study  Design Figure 6.a to be consistent with the eligibilit y criteria. 3.
Correct timing of AE assessments (Secti on 6.1). 4.
Revise minimum age- related inclusio n criterion and add cl arificat ion regarding patient sex 5.
(Secti on 7.1).
Clarify  the defini tion of 1 cycle of pri or systemic regimen and replace “ant ineoplast ic” wit h 6.
“anticancer” (Secti on 7.2).
Update Table 8.a (Recommended Brigat inib Dose Reduction Levels). 7.
Update Table 8.b (Brigatinib Dose Modification Recommendations for Treatment- Related 8.
Adverse Events).
For non-commercial use only
For non-commercial use only
Brigatinib (AP26113)
Study No. 2002 Page 97of 97
Protocol Incorporating Amendment No. 5 12 February 2021
CONFIDENTIALAmendment 1 DE v1 
Rationale for Amendment 1 DE v 1
The primary  reason for thi s amendment was to address requests about radiat ion exposure and 
minor technical edit ing from the Ethikko mmissio n der Med. Fak. HD (Ethics Committee of the 
Medical Facult y of Heidelberg Universit y) during ini tial assessment.
Chang es in Amendment 1 DE v1
1.Clarificat ion of inclusio n criteria for brain imaging in Germany  to be consi stent wi th 
standard of care and recent changes to the Radiat ion Protection Act.
2.Clarificat ion of statist ical analysis used for the primary endpo int.
3.Clarification of  sample size.
4.Clarificat ion of statist ical method used for interim analysis.
Amendment 1 SE v 1
Rationale for Amendment 1 SE v 1
The primary  reasons for thi s amendment was to update the dose escalation schedule of events 
and to clarify  that pati ent consent was required to receive treatment bey ond progressi on.
Changes in Amendment 1 SE v 1
Patient consent was requi red before patients could receive treatment bey ond progressi on. The 
dose escalat ion schedule was updated.
Amendment 1 (Global)
Rationale for Amendment 1
The primary  reasons for thi s amendment were to update the dose escalation schedule of events 
and clarify that patient consent is required to receive treatment beyond progression. 
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion purposes only .
Changes in Amendment 1
Patients are requi red to provi de consent to receive an increased dose of brigat inib (240 mg 1.
QD).
Risk factors (such as tobacco and alcohol intake) will be captured during screening. 2.
Updates to the schedule of events for treatment cont inuat ion at 240 mg QD after progression. 3.
For non-commercial use only
For non-commercial use only